<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39335111</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2072-6694</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3139</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers16183139</ELocationID><Abstract><AbstractText>Enteroviruses, with their diverse clinical manifestations ranging from mild or asymptomatic infections to severe diseases such as poliomyelitis and viral myocarditis, present a public health threat. However, they can also be used as oncolytic agents. This review shows the intricate relationship between enteroviruses and host cell factors. Enteroviruses utilize specific receptors and coreceptors for cell entry that are critical for infection and subsequent viral replication. These receptors, many of which are glycoproteins, facilitate virus binding, capsid destabilization, and internalization into cells, and their expression defines virus tropism towards various types of cells. Since enteroviruses can exploit different receptors, they have high oncolytic potential for personalized cancer therapy, as exemplified by the antitumor activity of certain enterovirus strains including the bioselected non-pathogenic Echovirus type 7/Rigvir, approved for melanoma treatment. Dissecting the roles of individual receptors in the entry of enteroviruses can provide valuable insights into their potential in cancer therapy. This review discusses the application of gene-targeting techniques such as CRISPR/Cas9 technology to investigate the impact of the loss of a particular receptor on the attachment of the virus and its subsequent internalization. It also summarizes the data on their expression in various types of cancer. By understanding how enteroviruses interact with specific cellular receptors, researchers can develop more effective regimens of treatment, offering hope for more targeted and efficient therapeutic strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alekseeva</LastName><ForeName>Olga N</ForeName><Initials>ON</Initials><Identifier Source="ORCID">0000-0003-3910-466X</Identifier><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoa</LastName><ForeName>Le T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vorobyev</LastName><ForeName>Pavel O</ForeName><Initials>PO</Initials><Identifier Source="ORCID">0000-0002-7567-913X</Identifier><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kochetkov</LastName><ForeName>Dmitriy V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gumennaya</LastName><ForeName>Yana D</ForeName><Initials>YD</Initials><Identifier Source="ORCID">0009-0006-5502-0676</Identifier><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naberezhnaya</LastName><ForeName>Elizaveta R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuvashov</LastName><ForeName>Denis O</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanov</LastName><ForeName>Alexander V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0002-5659-9679</Identifier><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chumakov</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-8078-2908</Identifier><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipatova</LastName><ForeName>Anastasia V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>19-74-10086</GrantID><Agency>Russian Science Foundation</Agency><Country /></Grant><Grant><GrantID>23-14-00370</GrantID><Agency>Russian Science Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRISPR/Cas9 technology</Keyword><Keyword MajorTopicYN="N">coxsackievirus</Keyword><Keyword MajorTopicYN="N">echovirus</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">oncolytic virus</Keyword><Keyword MajorTopicYN="N">viral receptors</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39335111</ArticleId><ArticleId IdType="pmc">PMC11430599</ArticleId><ArticleId IdType="doi">10.3390/cancers16183139</ArticleId><ArticleId IdType="pii">cancers16183139</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vorobyev P.O., Babaeva F.E., Panova A.V., Shakiba J., Kravchenko S.K., Soboleva A.V., Lipatova A.V. Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases. Mol. Biol. 2022;56:684–695. doi: 10.1134/S0026893322050144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0026893322050144</ArticleId><ArticleId IdType="pmc">PMC9534467</ArticleId><ArticleId IdType="pubmed">36217339</ArticleId></ArticleIdList></Reference><Reference><Citation>Genoni A., Canducci F., Rossi A., Broccolo F., Chumakov K., Bono G., Salerno-Uriarte J., Salvatoni A., Pugliese A., Toniolo A. Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach. Sci. Rep. 2017;7:5013. doi: 10.1038/s41598-017-04993-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04993-y</ArticleId><ArticleId IdType="pmc">PMC5504018</ArticleId><ArticleId IdType="pubmed">28694527</ArticleId></ArticleIdList></Reference><Reference><Citation>Fieldhouse J.K., Wang X., Mallinson K.A., Tsao R.W., Gray G.C. A systematic review of evidence that enteroviruses may be zoonotic. Emerg. Microbes Infect. 2018;7:164. doi: 10.1038/s41426-018-0159-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0159-1</ArticleId><ArticleId IdType="pmc">PMC6158190</ArticleId><ArticleId IdType="pubmed">30258048</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.H., Wang K., Zhao K., Hua S.C., Du J. The Structure, Function, and Mechanisms of Action of Enterovirus Non-structural Protein 2C. Front. Microbiol. 2020;11:615965. doi: 10.3389/fmicb.2020.615965.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.615965</ArticleId><ArticleId IdType="pmc">PMC7767853</ArticleId><ArticleId IdType="pubmed">33381104</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:368–381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergelson J.M., Coyne C.B. Picornavirus entry. Adv. Exp. Med. Biol. 2013;790:24–41. doi: 10.1007/978-1-4614-7651-1_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-7651-1_2</ArticleId><ArticleId IdType="pubmed">23884584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer J., Schelhaas M., Helenius A. Virus entry by endocytosis. Annu. Rev. Biochem. 2010;79:803–833. doi: 10.1146/annurev-biochem-060208-104626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-060208-104626</ArticleId><ArticleId IdType="pubmed">20196649</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinshaw J.E. Dynamin and its role in membrane fission. Annu. Rev. Cell Dev. Biol. 2000;16:483–519. doi: 10.1146/annurev.cellbio.16.1.483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.16.1.483</ArticleId><ArticleId IdType="pmc">PMC4781412</ArticleId><ArticleId IdType="pubmed">11031245</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer J., Helenius A. Gulping rather than sipping: Macropinocytosis as a way of virus entry. Curr. Opin. Microbiol. 2012;15:490–499. doi: 10.1016/j.mib.2012.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2012.05.016</ArticleId><ArticleId IdType="pubmed">22749376</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K., Haucke V. Clathrin-mediated endocytosis: Membrane factors pull the trigger. Trends Cell Biol. 2001;11:385–391. doi: 10.1016/S0962-8924(01)02082-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(01)02082-7</ArticleId><ArticleId IdType="pubmed">11514193</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair W., Omar M.  Enteroviruses. StatPearls Publishing; Treasure Island, FL, USA: 2023.  [(accessed on 28 April 2024)].  Available online:  https://www.ncbi.nlm.nih.gov/books/NBK562330/</Citation></Reference><Reference><Citation>Voroshilova M.K. Potential use of nonpathogenic enteroviruses for control of human disease. Prog. Med. Virol. 1989;36:191–202.</Citation><ArticleIdList><ArticleId IdType="pubmed">2555836</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K., Benn C.S., Aaby P., Kottilil S., Gallo R. Can existing live vaccines prevent COVID-19? Science. 2020;368:1187–1188. doi: 10.1126/science.abc4262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc4262</ArticleId><ArticleId IdType="pubmed">32527819</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M.P., Voroshilova M.K., Antsupova A.S., Boiko V.M., Blinova M.I., Priimyagi L.S., Rodin V.I., Seibil V.B., Sinyak K.M., Smorodintsev A.A., et al. Live enterovirus vaccines for the urgent nonspecific prevention of mass respiratory diseases during autumn and winter epidemics of influenza and acute respiratory diseses. J. Microbiol. Epidemiol. Immunol. 1992;11:37–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">1338742</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov P.M., Morozova V.V., Babkin I.V., Baikov I.K., Netesov S.V., Tikunova N.V. Oncolytic enteroviruses. Mol. Biol. 2012;46:712–725. doi: 10.1134/S0026893312050032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0026893312050032</ArticleId><ArticleId IdType="pubmed">23156670</ArticleId></ArticleIdList></Reference><Reference><Citation>Donina S., Strele I., Proboka G., Auzins J., Alberts P., Jonsson B., Venskus D., Muceniece A. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25:421–426. doi: 10.1097/CMR.0000000000000180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CMR.0000000000000180</ArticleId><ArticleId IdType="pmc">PMC4560272</ArticleId><ArticleId IdType="pubmed">26193376</ArticleId></ArticleIdList></Reference><Reference><Citation>Babiker H.M., Riaz I.B., Husnain M., Borad M.J. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virotherapy. 2017;6:11–18. doi: 10.2147/OV.S100072.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OV.S100072</ArticleId><ArticleId IdType="pmc">PMC5308590</ArticleId><ArticleId IdType="pubmed">28224120</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley S., Jakes A.D., Harrington K., Pandha H., Melcher A., Errington-Mais F. Applications of coxsackievirus A21 in oncology. Oncolytic Virotherapy. 2014;3:47–55. doi: 10.2147/OV.S56322.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OV.S56322</ArticleId><ArticleId IdType="pmc">PMC4918364</ArticleId><ArticleId IdType="pubmed">27512662</ArticleId></ArticleIdList></Reference><Reference><Citation>Yla-Pelto J., Tripathi L., Susi P. Therapeutic Use of Native and Recombinant Enteroviruses. Viruses. 2016;8:57. doi: 10.3390/v8030057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8030057</ArticleId><ArticleId IdType="pmc">PMC4810247</ArticleId><ArticleId IdType="pubmed">26907330</ArticleId></ArticleIdList></Reference><Reference><Citation>Desjardins A., Gromeier M., Herndon J.E., II, Beaubier N., Bolognesi D.P., Friedman A.H., Friedman H.S., McSherry F., Muscat A.M., Nair S., et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N. Engl. J. Med. 2018;379:150–161. doi: 10.1056/NEJMoa1716435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1716435</ArticleId><ArticleId IdType="pmc">PMC6065102</ArticleId><ArticleId IdType="pubmed">29943666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoa L.T. Ph.D. Thesis. Moscow Institute of Physics and Technology; Moscow, Russia: 2020. Development of Diagnoatic Panels of Knockout Cells for Functional Classification of Enteroviruses.</Citation></Reference><Reference><Citation>Lipatova A.V. Ph.D. Thesis. Engelhardt Institute of Molecular Biology (EIMB), RAS; Moscow, Russia: 2017. Non-Pathogenic Strain of Human Enterovirus, Related to Coxsackievirus B5 as a Model for Study Viral Oncolysis.</Citation></Reference><Reference><Citation>Zhao X., Zhang G., Liu S., Chen X., Peng R., Dai L., Qu X., Li S., Song H., Gao Z., et al. Human Neonatal Fc Receptor Is the Cellular Uncoating Receptor for Enterovirus B. Cell. 2019;177:1553–1565.e1516. doi: 10.1016/j.cell.2019.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.04.035</ArticleId><ArticleId IdType="pmc">PMC7111318</ArticleId><ArticleId IdType="pubmed">31104841</ArticleId></ArticleIdList></Reference><Reference><Citation>Flint S.J., Enquist L.W., Racaniello V.R., Rall G.F., Skalka A.M. Principal of Virology. Volume 1 ASM Press; Washington, DC, USA: 2015.</Citation></Reference><Reference><Citation>Kanai R., Zaupa C., Sgubin D., Antoszczyk S.J., Martuza R.L., Wakimoto H., Rabkin S.D. Effect of gamma34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J. Virol. 2012;86:4420–4431. doi: 10.1128/JVI.00017-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00017-12</ArticleId><ArticleId IdType="pmc">PMC3318611</ArticleId><ArticleId IdType="pubmed">22345479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano K., Asano R., Tsumoto K., Kwon H., Goins W.F., Kumagai I., Cohen J.B., Glorioso J.C. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol. Ther. 2005;11:617–626. doi: 10.1016/j.ymthe.2004.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2004.12.012</ArticleId><ArticleId IdType="pubmed">15771964</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M., Yang C.S., Guo W., Tang J., Huang Q., Feng S., Jiang A., Xu X., Jiang G., Liu Y.Q. A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy. Cancer Biol. Ther. 2017;18:833–840. doi: 10.1080/15384047.2017.1395115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384047.2017.1395115</ArticleId><ArticleId IdType="pmc">PMC5710672</ArticleId><ArticleId IdType="pubmed">29144842</ArticleId></ArticleIdList></Reference><Reference><Citation>Loya S.M., Zhang X. Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator. Gene Ther. 2015;22:237–246. doi: 10.1038/gt.2014.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2014.113</ArticleId><ArticleId IdType="pmc">PMC4352111</ArticleId><ArticleId IdType="pubmed">25567538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie S., Fan W., Yang C., Lei W., Pan H., Tong X., Wu Y., Wang S. Beclin1-armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R-CHOP against lymphoma in vitro and in vivo. Oncol. Rep. 2021;45:987–996. doi: 10.3892/or.2021.7942.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2021.7942</ArticleId><ArticleId IdType="pmc">PMC7860022</ArticleId><ArticleId IdType="pubmed">33469679</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouljenko D.V., Ding J., Lee I.F., Murad Y.M., Bu X., Liu G., Delwar Z., Sun Y., Yu S., Samudio I., et al. Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes. Biomedicines. 2020;8:484. doi: 10.3390/biomedicines8110484.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8110484</ArticleId><ArticleId IdType="pmc">PMC7695276</ArticleId><ArticleId IdType="pubmed">33182232</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeois-Daigneault M.C., Roy D.G., Falls T., Twumasi-Boateng K., St-Germain L.E., Marguerie M., Garcia V., Selman M., Jennings V.A., Pettigrew J., et al. Oncolytic vesicular stomatitis virus expressing interferon-gamma has enhanced therapeutic activity. Mol. Ther. Oncolytics. 2016;3:16001. doi: 10.1038/mto.2016.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mto.2016.1</ArticleId><ArticleId IdType="pmc">PMC4824565</ArticleId><ArticleId IdType="pubmed">27119116</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Ravindranathan R., Li J., Kalinski P., Guo Z.S., Bartlett D.L. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology. 2016;5:e1091554. doi: 10.1080/2162402X.2015.1091554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2015.1091554</ArticleId><ArticleId IdType="pmc">PMC4839379</ArticleId><ArticleId IdType="pubmed">27141352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietanen E., Koivu M.K.A., Susi P. Cytolytic Properties and Genome Analysis of Rigvir((R)) Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates. Viruses. 2022;14:525. doi: 10.3390/v14030525.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14030525</ArticleId><ArticleId IdType="pmc">PMC8949920</ArticleId><ArticleId IdType="pubmed">35336934</ArticleId></ArticleIdList></Reference><Reference><Citation>Svyatchenko V.A., Ternovoy V.A., Kiselev N.N., Demina A.V., Loktev V.B., Netesov S.V., Chumakov P.M. Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines. Arch. Virol. 2017;162:3355–3362. doi: 10.1007/s00705-017-3492-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-017-3492-0</ArticleId><ArticleId IdType="pubmed">28766058</ArticleId></ArticleIdList></Reference><Reference><Citation>Alekseeva O., Gumennaya Y., Naberezhnaya E., Kushchenko A., Dmitriev S., Chumakov P., Lipatova A. B37. An integrated approach reveals oncolytic activity and novel receptor requirements of bioselected echovirus variants; Proceedings of the Viruses 2024—A World of Viruses; Barcelona, Spain. 14–16 February 2024; p. 189.</Citation></Reference><Reference><Citation>Zhang P., Mueller S., Morais M.C., Bator C.M., Bowman V.D., Hafenstein S., Wimmer E., Rossmann M.G. Crystal structure of CD155 and electron microscopic studies of its complexes with polioviruses. Proc. Natl. Acad. Sci. USA. 2008;105:18284–18289. doi: 10.1073/pnas.0807848105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807848105</ArticleId><ArticleId IdType="pmc">PMC2587566</ArticleId><ArticleId IdType="pubmed">19011098</ArticleId></ArticleIdList></Reference><Reference><Citation>Belnap D.M., McDermott B.M., Jr., Filman D.J., Cheng N., Trus B.L., Zuccola H.J., Racaniello V.R., Hogle J.M., Steven A.C. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl. Acad. Sci. USA. 2000;97:73–78. doi: 10.1073/pnas.97.1.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.1.73</ArticleId><ArticleId IdType="pmc">PMC26618</ArticleId><ArticleId IdType="pubmed">10618373</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandenburg B., Lee L.Y., Lakadamyali M., Rust M.J., Zhuang X., Hogle J.M. Imaging poliovirus entry in live cells. PLoS Biol. 2007;5:e183. doi: 10.1371/journal.pbio.0050183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0050183</ArticleId><ArticleId IdType="pmc">PMC1914398</ArticleId><ArticleId IdType="pubmed">17622193</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhand S., Hosseini S.M., Tabarraei A., Moradi A., Saeidi M. Analysis of poliovirus receptor, CD155 expression in different human colorectal cancer cell lines: Implications for poliovirus virotherapy. J. Cancer Res. Ther. 2019;15:61–67. doi: 10.4103/jcrt.JCRT_13_17.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jcrt.JCRT_13_17</ArticleId><ArticleId IdType="pubmed">30880756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowers J.R., Readler J.M., Sharma P., Excoffon K. Poliovirus Receptor: More than a simple viral receptor. Virus Res. 2017;242:1–6. doi: 10.1016/j.virusres.2017.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2017.09.001</ArticleId><ArticleId IdType="pmc">PMC5650920</ArticleId><ArticleId IdType="pubmed">28870470</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello V.R. Early events in poliovirus infection: Virus-receptor interactions. Proc. Natl. Acad. Sci. USA. 1996;93:11378–11381. doi: 10.1073/pnas.93.21.11378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.21.11378</ArticleId><ArticleId IdType="pmc">PMC38065</ArticleId><ArticleId IdType="pubmed">8876143</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson W.T., Coyne C.B. Enteroviruses: Omics, Molecular Biology, and Control. Caister Academic Press; Poole, UK: 2018.</Citation></Reference><Reference><Citation>Chen X., Qu X., Liu C., Zhang Y., Zhang G., Han P., Duan Y., Li Q., Wang L., Ruan W., et al. Human FcRn Is a Two-in-One Attachment-Uncoating Receptor for Echovirus 18. mBio. 2022;13:e0116622. doi: 10.1128/mbio.01166-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01166-22</ArticleId><ArticleId IdType="pmc">PMC9426509</ArticleId><ArticleId IdType="pubmed">35862785</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandesande H., Laajala M., Kantoluoto T., Ruokolainen V., Lindberg A.M., Marjomaki V. Early Entry Events in Echovirus 30 Infection. J. Virol. 2020;94:10–1128. doi: 10.1128/JVI.00592-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00592-20</ArticleId><ArticleId IdType="pmc">PMC7307138</ArticleId><ArticleId IdType="pubmed">32295914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.W., Lin H.Y., Tsou Y.L., Chitra E., Hsiao K.N., Shao H.Y., Liu C.C., Sia C., Chong P., Chow Y.H. Human SCARB2-mediated entry and endocytosis of EV71. PLoS ONE. 2012;7:e30507. doi: 10.1371/journal.pone.0030507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030507</ArticleId><ArticleId IdType="pmc">PMC3260287</ArticleId><ArticleId IdType="pubmed">22272359</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Liu Q., Wu X., Chen P., Wu X., Guo Y., Liu S., Liang Z., Fan C., Wang Y. A safe and sensitive enterovirus A71 infection model based on human SCARB2 knock-in mice. Vaccine. 2016;34:2729–2736. doi: 10.1016/j.vaccine.2016.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.04.029</ArticleId><ArticleId IdType="pubmed">27102822</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S.L., Chung N.H., Lin Y.C., Liao Y.A., Chen Y.C., Chow Y.H. Human SCARB2 Acts as a Cellular Associator for Helping Coxsackieviruses A10 Infection. Viruses. 2023;15:932. doi: 10.3390/v15040932.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040932</ArticleId><ArticleId IdType="pmc">PMC10144829</ArticleId><ArticleId IdType="pubmed">37112912</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Iizuka S., Yamashita T., Minagawa H., Mizuta K., Okamoto M., Nishimura H., Sanjoh K., Katsushima N., Itagaki T., et al. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J. Virol. 2012;86:5686–5696. doi: 10.1128/JVI.00020-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00020-12</ArticleId><ArticleId IdType="pmc">PMC3347270</ArticleId><ArticleId IdType="pubmed">22438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjomaki V., Pietiainen V., Matilainen H., Upla P., Ivaska J., Nissinen L., Reunanen H., Huttunen P., Hyypia T., Heino J. Internalization of echovirus 1 in caveolae. J. Virol. 2002;76:1856–1865. doi: 10.1128/JVI.76.4.1856-1865.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.4.1856-1865.2002</ArticleId><ArticleId IdType="pmc">PMC135881</ArticleId><ArticleId IdType="pubmed">11799180</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulli T., Koivunen E., Hyypia T. Cell-surface interactions of echovirus 22. J. Biol. Chem. 1997;272:21176–21180. doi: 10.1074/jbc.272.34.21176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.34.21176</ArticleId><ArticleId IdType="pubmed">9261123</ArticleId></ArticleIdList></Reference><Reference><Citation>Merilahti P., Koskinen S., Heikkila O., Karelehto E., Susi P. Endocytosis of integrin-binding human picornaviruses. Adv. Virol. 2012;2012:547530. doi: 10.1155/2012/547530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/547530</ArticleId><ArticleId IdType="pmc">PMC3514805</ArticleId><ArticleId IdType="pubmed">23227048</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelsson S., Gullberg M., Jonsson N., Roivainen M., Edman K., Lindberg A.M. Studies of Echovirus 5 interactions with the cell surface: Heparan sulfate mediates attachment to the host cell. Virus Res. 2010;151:170–176. doi: 10.1016/j.virusres.2010.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2010.05.001</ArticleId><ArticleId IdType="pubmed">20466025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergelson J.M., St John N., Kawaguchi S., Chan M., Stubdal H., Modlin J., Finberg R.W. Infection by echoviruses 1 and 8 depends on the alpha 2 subunit of human VLA-2. J. Virol. 1993;67:6847–6852. doi: 10.1128/jvi.67.11.6847-6852.1993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.67.11.6847-6852.1993</ArticleId><ArticleId IdType="pmc">PMC238130</ArticleId><ArticleId IdType="pubmed">8411387</ArticleId></ArticleIdList></Reference><Reference><Citation>Staring J., van den Hengel L.G., Raaben M., Blomen V.A., Carette J.E., Brummelkamp T.R. KREMEN1 Is a Host Entry Receptor for a Major Group of Enteroviruses. Cell Host Microbe. 2018;23:636–643.e635. doi: 10.1016/j.chom.2018.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.03.019</ArticleId><ArticleId IdType="pubmed">29681460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Zhou D., Ni T., Karia D., Kotecha A., Wang X., Rao Z., Jones E.Y., Fry E.E., Ren J., et al. Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10. Nat. Commun. 2020;11:38. doi: 10.1038/s41467-019-13936-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13936-2</ArticleId><ArticleId IdType="pmc">PMC6946704</ArticleId><ArticleId IdType="pubmed">31911601</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao C., Bator C.M., Bowman V.D., Rieder E., He Y., Hebert B., Bella J., Baker T.S., Wimmer E., Kuhn R.J., et al. Interaction of coxsackievirus A21 with its cellular receptor, ICAM-1. J. Virol. 2001;75:2444–2451. doi: 10.1128/JVI.75.5.2444-2451.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.5.2444-2451.2001</ArticleId><ArticleId IdType="pmc">PMC114827</ArticleId><ArticleId IdType="pubmed">11160747</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao C., Bator-Kelly C.M., Rieder E., Chipman P.R., Craig A., Kuhn R.J., Wimmer E., Rossmann M.G. The crystal structure of coxsackievirus A21 and its interaction with ICAM-1. Structure. 2005;13:1019–1033. doi: 10.1016/j.str.2005.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2005.04.011</ArticleId><ArticleId IdType="pubmed">16004874</ArticleId></ArticleIdList></Reference><Reference><Citation>Selinka H.C., Wolde A., Sauter M., Kandolf R., Klingel K. Virus-receptor interactions of coxsackie B viruses and their putative influence on cardiotropism. Med. Microbiol. Immunol. 2004;193:127–131. doi: 10.1007/s00430-003-0193-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-003-0193-y</ArticleId><ArticleId IdType="pubmed">12920584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y., Xiong S. Exosomes mediate Coxsackievirus B3 transmission and expand the viral tropism. PLoS Pathog. 2023;19:e1011090. doi: 10.1371/journal.ppat.1011090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011090</ArticleId><ArticleId IdType="pmc">PMC9888687</ArticleId><ArticleId IdType="pubmed">36634130</ArticleId></ArticleIdList></Reference><Reference><Citation>Excoffon K. The coxsackievirus and adenovirus receptor: Virological and biological beauty. FEBS Lett. 2020;594:1828–1837. doi: 10.1002/1873-3468.13794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.13794</ArticleId><ArticleId IdType="pubmed">32298477</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Chipman P.R., Howitt J., Bator C.M., Whitt M.A., Baker T.S., Kuhn R.J., Anderson C.W., Freimuth P., Rossmann M.G. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat. Struct. Biol. 2001;8:874–878. doi: 10.1038/nsb1001-874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsb1001-874</ArticleId><ArticleId IdType="pmc">PMC4152846</ArticleId><ArticleId IdType="pubmed">11573093</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell R.L., Landau B.J., Philipson L. The early interaction of coxsackievirus B3 with HeLa cells. Proc. Soc. Exp. Biol. Med. 1971;137:1082–1088. doi: 10.3181/00379727-137-35732.</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-137-35732</ArticleId><ArticleId IdType="pubmed">5560655</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Hafenstein S., Harris K.G., Cifuente J.O., Zhang Y., Bowman V.D., Chipman P.R., Bator C.M., Lin F., Medof M.E., et al. Interaction of decay-accelerating factor with echovirus 7. J. Virol. 2010;84:12665–12674. doi: 10.1128/JVI.00837-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00837-10</ArticleId><ArticleId IdType="pmc">PMC3004353</ArticleId><ArticleId IdType="pubmed">20881044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafenstein S., Bowman V.D., Chipman P.R., Bator Kelly C.M., Lin F., Medof M.E., Rossmann M.G. Interaction of decay-accelerating factor with coxsackievirus B3. J. Virol. 2007;81:12927–12935. doi: 10.1128/JVI.00931-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00931-07</ArticleId><ArticleId IdType="pmc">PMC2169128</ArticleId><ArticleId IdType="pubmed">17804498</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnauchow T.M., Tolson D.L., Harrison B.A., Altman E., Lublin D.M., Dimock K. The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55) J. Virol. 1996;70:5143–5152. doi: 10.1128/jvi.70.8.5143-5152.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.70.8.5143-5152.1996</ArticleId><ArticleId IdType="pmc">PMC190469</ArticleId><ArticleId IdType="pubmed">8764022</ArticleId></ArticleIdList></Reference><Reference><Citation>Shieh J.T., Bergelson J.M. Interaction with decay-accelerating factor facilitates coxsackievirus B infection of polarized epithelial cells. J. Virol. 2002;76:9474–9480. doi: 10.1128/JVI.76.18.9474-9480.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.18.9474-9480.2002</ArticleId><ArticleId IdType="pmc">PMC136423</ArticleId><ArticleId IdType="pubmed">12186929</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe N.G., Beagley L.G., Christiansen D., Loveland B.E., Johansson E.S., Beagley K.W., Barry R.D., Shafren D.R. Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity. J. Virol. 2004;78:12677–12682. doi: 10.1128/JVI.78.22.12677-12682.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.22.12677-12682.2004</ArticleId><ArticleId IdType="pmc">PMC525106</ArticleId><ArticleId IdType="pubmed">15507656</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Lin F., Chipman P.R., Bator C.M., Baker T.S., Shoham M., Kuhn R.J., Medof M.E., Rossmann M.G. Structure of decay-accelerating factor bound to echovirus 7: A virus-receptor complex. Proc. Natl. Acad. Sci. USA. 2002;99:10325–10329. doi: 10.1073/pnas.152161599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.152161599</ArticleId><ArticleId IdType="pmc">PMC124913</ArticleId><ArticleId IdType="pubmed">12119400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren D.R., Dorahy D.J., Ingham R.A., Burns G.F., Barry R.D. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J. Virol. 1997;71:4736–4743. doi: 10.1128/jvi.71.6.4736-4743.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.71.6.4736-4743.1997</ArticleId><ArticleId IdType="pmc">PMC191695</ArticleId><ArticleId IdType="pubmed">9151867</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaikin A.V., Novoselov A.V., Sergeev A.G., Fadeyev F.A., Lebedev S.V. Two clusters of mutations map distinct receptor-binding sites of echovirus 11 for the decay-accelerating factor (CD55) and for canyon-binding receptors. Virus Res. 2009;145:74–79. doi: 10.1016/j.virusres.2009.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2009.06.004</ArticleId><ArticleId IdType="pubmed">19540285</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren D.R., Bates R.C., Agrez M.V., Herd R.L., Burns G.F., Barry R.D. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J. Virol. 1995;69:3873–3877. doi: 10.1128/jvi.69.6.3873-3877.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.69.6.3873-3877.1995</ArticleId><ArticleId IdType="pmc">PMC189108</ArticleId><ArticleId IdType="pubmed">7538177</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhella D., Goodfellow I.G., Roversi P., Pettigrew D., Chaudhry Y., Evans D.J., Lea S.M. The structure of echovirus type 12 bound to a two-domain fragment of its cellular attachment protein decay-accelerating factor (CD 55) J. Biol. Chem. 2004;279:8325–8332. doi: 10.1074/jbc.M311334200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311334200</ArticleId><ArticleId IdType="pubmed">14634014</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B.L., Garrido-Laguna I. TIGIT: A novel immunotherapy target moving from bench to bedside. Cancer Immunol. Immunother. 2018;67:1659–1667. doi: 10.1007/s00262-018-2246-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-018-2246-5</ArticleId><ArticleId IdType="pmc">PMC11028339</ArticleId><ArticleId IdType="pubmed">30232519</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X., Harden K., Gonzalez L.C., Francesco M., Chiang E., Irving B., Tom I., Ivelja S., Refino C.J., Clark H., et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 2009;10:48–57. doi: 10.1038/ni.1674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1674</ArticleId><ArticleId IdType="pubmed">19011627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Du J., Wang H., Chen C., Jiao L., Cheng X., Zhou X., Chen S., Gou S., Zhao W., et al. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR. Cell Commun. Signal. 2020;18:142. doi: 10.1186/s12964-020-00638-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-020-00638-2</ArticleId><ArticleId IdType="pmc">PMC7487564</ArticleId><ArticleId IdType="pubmed">32894141</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne C.B., Kim K.S., Bergelson J.M. Poliovirus entry into human brain microvascular cells requires receptor-induced activation of SHP-2. EMBO J. 2007;26:4016–4028. doi: 10.1038/sj.emboj.7601831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601831</ArticleId><ArticleId IdType="pmc">PMC1994131</ArticleId><ArticleId IdType="pubmed">17717529</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengel K.F., Harden-Bowles K., Yu X., Rouge L., Yin J., Comps-Agrar L., Wiesmann C., Bazan J.F., Eaton D.L., Grogan J.L. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc. Natl. Acad. Sci. USA. 2012;109:5399–5404. doi: 10.1073/pnas.1120606109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1120606109</ArticleId><ArticleId IdType="pmc">PMC3325733</ArticleId><ArticleId IdType="pubmed">22421438</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike S., Horie H., Ise I., Okitsu A., Yoshida M., Iizuka N., Takeuchi K., Takegami T., Nomoto A. The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J. 1990;9:3217–3224. doi: 10.1002/j.1460-2075.1990.tb07520.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1990.tb07520.x</ArticleId><ArticleId IdType="pmc">PMC552052</ArticleId><ArticleId IdType="pubmed">2170108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylipaasto P., Eskelinen M., Salmela K., Hovi T., Roivainen M. Vitronectin receptors, alpha v integrins, are recognized by several non-RGD-containing echoviruses in a continuous laboratory cell line and also in primary human Langerhans’ islets and endothelial cells. J. Gen. Virol. 2010;91:155–165. doi: 10.1099/vir.0.012450-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.012450-0</ArticleId><ArticleId IdType="pubmed">19776235</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing L., Huhtala M., Pietiainen V., Kapyla J., Vuorinen K., Marjomaki V., Heino J., Johnson M.S., Hyypia T., Cheng R.H. Structural and functional analysis of integrin alpha2I domain interaction with echovirus 1. J. Biol. Chem. 2004;279:11632–11638. doi: 10.1074/jbc.M312441200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M312441200</ArticleId><ArticleId IdType="pubmed">14701832</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietiäinen V., Marjomäki V., Upla P., Pelkmans L., Helenius A., Hyypiä T. Echovirus 1 endocytosis into caveosomes requires lipid rafts, dynamin II, and signaling events. Mol. Biol. Cell. 2004;15:4911–4925. doi: 10.1091/mbc.e04-01-0070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e04-01-0070</ArticleId><ArticleId IdType="pmc">PMC524743</ArticleId><ArticleId IdType="pubmed">15356270</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant R.A., Hiremath C.N., Filman D.J., Syed R., Andries K., Hogle J.M. Structures of poliovirus complexes with anti-viral drugs: Implications for viral stability and drug design. Curr. Biol. 1994;4:784–797. doi: 10.1016/S0960-9822(00)00176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(00)00176-7</ArticleId><ArticleId IdType="pubmed">7820548</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss M., Filman D.J., Belnap D.M., Cheng N., Noel R.T., Hogle J.M. Nectin-like interactions between poliovirus and its receptor trigger conformational changes associated with cell entry. J. Virol. 2015;89:4143–4157. doi: 10.1128/JVI.03101-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03101-14</ArticleId><ArticleId IdType="pmc">PMC4442392</ArticleId><ArticleId IdType="pubmed">25631086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogle J.M. Poliovirus cell entry: Common structural themes in viral cell entry pathways. Annu. Rev. Microbiol. 2002;56:677–702. doi: 10.1146/annurev.micro.56.012302.160757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.56.012302.160757</ArticleId><ArticleId IdType="pmc">PMC1500891</ArticleId><ArticleId IdType="pubmed">12142481</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.S., Lee K., Bae S., Park J., Lee C.K., Kim M., Kim E., Kim M., Kim S., Kim C., et al. CRISPR/Cas9-mediated gene knockout screens and target identification via whole-genome sequencing uncover host genes required for picornavirus infection. J. Biol. Chem. 2017;292:10664–10671. doi: 10.1074/jbc.M117.782425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.782425</ArticleId><ArticleId IdType="pmc">PMC5481571</ArticleId><ArticleId IdType="pubmed">28446605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi S.S., Sawant S., Gohil T., Lambe U., Sangal L., Patel D., Krishnasamy K., Ghoshal U., Harvey P., Deshpande J. Poliovirus nonpermissive CD155 knockout cells derived from RD cell line for handling poliovirus potentially infectious materials in virology laboratories. J. Med. Virol. 2022;94:4901–4909. doi: 10.1002/jmv.27897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27897</ArticleId><ArticleId IdType="pubmed">35642597</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosnovtseva A.O., Lipatova A.V., Grinenko N.F., Baklaushev V.P., Chumakov P.M., Chekhonin V.P. Sensitivity of C6 Glioma Cells Carrying the Human Poliovirus Receptor to Oncolytic Polioviruses. Bull. Exp. Biol. Med. 2016;161:821–825. doi: 10.1007/s10517-016-3520-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10517-016-3520-1</ArticleId><ArticleId IdType="pubmed">27783287</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Braak W.J.P., Monica B., Limpens D., Rockx-Brouwer D., de Boer M., Oosterhoff D. Construction of a Vero Cell Line Expressing Human ICAM1 for the Development of Rhinovirus Vaccines. Viruses. 2022;14:2235. doi: 10.3390/v14102235.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102235</ArticleId><ArticleId IdType="pmc">PMC9607643</ArticleId><ArticleId IdType="pubmed">36298792</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla S.D., Shastri M.D., Vanka S.K., Jha N.K., Dureja H., Gupta G., Chellappan D.V.K., Oliver B.G., Dua K., Walters E.H. Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce rhinovirus-induced acute exacerbations in chronic respiratory diseases. Inflammopharmacology. 2022;30:725–735. doi: 10.1007/s10787-022-00968-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00968-2</ArticleId><ArticleId IdType="pmc">PMC8938636</ArticleId><ArticleId IdType="pubmed">35316427</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang M., Wang X., Wang Q., Wang Y., Lin J., Sun Y., Li X., Zhang L., Lou Z., Wang J., et al. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell. 2014;5:692–703. doi: 10.1007/s13238-014-0087-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0087-3</ArticleId><ArticleId IdType="pmc">PMC4145081</ArticleId><ArticleId IdType="pubmed">24986489</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Koike S. Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection. J. Virol. 2011;85:4937–4946. doi: 10.1128/JVI.02358-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02358-10</ArticleId><ArticleId IdType="pmc">PMC3126200</ArticleId><ArticleId IdType="pubmed">21389126</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuronita T., Eskelinen E.L., Fujita H., Saftig P., Himeno M., Tanaka Y. A role for the lysosomal membrane protein LGP85 in the biogenesis and maintenance of endosomal and lysosomal morphology. J. Cell Sci. 2002;115:4117–4131. doi: 10.1242/jcs.00075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.00075</ArticleId><ArticleId IdType="pubmed">12356916</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskelinen E.L., Tanaka Y., Saftig P. At the acidic edge: Emerging functions for lysosomal membrane proteins. Trends Cell Biol. 2003;13:137–145. doi: 10.1016/S0962-8924(03)00005-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(03)00005-9</ArticleId><ArticleId IdType="pubmed">12628346</ArticleId></ArticleIdList></Reference><Reference><Citation>Heybrock S., Kanerva K., Meng Y., Ing C., Liang A., Xiong Z.J., Weng X., Ah Kim Y., Collins R., Trimble W., et al. Lysosomal integral membrane protein-2 (LIMP-2/SCARB2) is involved in lysosomal cholesterol export. Nat. Commun. 2019;10:3521. doi: 10.1038/s41467-019-11425-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11425-0</ArticleId><ArticleId IdType="pmc">PMC6684646</ArticleId><ArticleId IdType="pubmed">31387993</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkovic S.F., Dibbens L.M., Oshlack A., Silver J.D., Katerelos M., Vears D.F., Lullmann-Rauch R., Blanz J., Zhang K.W., Stankovich J., et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am. J. Hum. Genet. 2008;82:673–684. doi: 10.1016/j.ajhg.2007.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2007.12.019</ArticleId><ArticleId IdType="pmc">PMC2427287</ArticleId><ArticleId IdType="pubmed">18308289</ArticleId></ArticleIdList></Reference><Reference><Citation>Velayati A., DePaolo J., Gupta N., Choi J.H., Moaven N., Westbroek W., Goker-Alpan O., Goldin E., Stubblefield B.K., Kolodny E., et al. A mutation in SCARB2 is a modifier in Gaucher disease. Hum. Mutat. 2011;32:1232–1238. doi: 10.1002/humu.21566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21566</ArticleId><ArticleId IdType="pmc">PMC3196787</ArticleId><ArticleId IdType="pubmed">21796727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y., Pei J., Wang Y., Chen Q., Sun M., Kang L., Zhang X., Zhang L., Gao X., Lin Z. The Deficiency of SCARB2/LIMP-2 Impairs Metabolism via Disrupted mTORC1-Dependent Mitochondrial OXPHOS. Int. J. Mol. Sci. 2022;23:8634. doi: 10.3390/ijms23158634.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23158634</ArticleId><ArticleId IdType="pmc">PMC9368982</ArticleId><ArticleId IdType="pubmed">35955761</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita H., Takata Y., Kono A., Tanaka Y., Takahashi T., Himeno M., Kato K. Isolation and sequencing of a cDNA clone encoding the 85 kDa human lysosomal sialoglycoprotein (hLGP85) in human metastatic pancreas islet tumor cells. Biochem. Biophys. Res. Commun. 1992;184:604–611. doi: 10.1016/0006-291X(92)90632-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(92)90632-U</ArticleId><ArticleId IdType="pubmed">1374238</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P., Song Z., Qi Y., Feng X., Xu N., Sun Y., Wu X., Yao X., Mao Q., Li X., et al. Molecular determinants of enterovirus 71 viral entry: Cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J. Biol. Chem. 2012;287:6406–6420. doi: 10.1074/jbc.M111.301622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.301622</ArticleId><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D., Zhao Y., Kotecha A., Fry E.E., Kelly J.T., Wang X., Rao Z., Rowlands D.J., Ren J., Stuart D.I. Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nat. Microbiol. 2019;4:414–419. doi: 10.1038/s41564-018-0319-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0319-z</ArticleId><ArticleId IdType="pubmed">30531980</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Yang P., Wang N., Zhang J., Li J., Guo H., Yin X., Rao Z., Wang X., Zhang L. The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection. Protein Cell. 2017;8:590–600. doi: 10.1007/s13238-017-0405-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-017-0405-7</ArticleId><ArticleId IdType="pmc">PMC5546930</ArticleId><ArticleId IdType="pubmed">28447294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke X., Li C., Luo D., Wang T., Liu Y., Tan Z., Du M., He Z., Wang H., Zheng Z., et al. Metabolic labeling of enterovirus 71 with quantum dots for the study of virus receptor usage. J. Nanobiotechnol. 2021;19:295. doi: 10.1186/s12951-021-01046-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-021-01046-5</ArticleId><ArticleId IdType="pmc">PMC8477995</ArticleId><ArticleId IdType="pubmed">34583708</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T., Koike S. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat. Med. 2009;15:798–801. doi: 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Sun T., Zhou G., Li D., Chen S., Zhang W., Li X., Zhang R., Yang H., Duan G. Pathogenesis study of enterovirus 71 using a novel human SCARB2 knock-in mouse model. mSphere. 2021;6:10–1128. doi: 10.1128/mSphere.01048-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.01048-20</ArticleId><ArticleId IdType="pmc">PMC8546711</ArticleId><ArticleId IdType="pubmed">33692197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.-W., Yu S.-L., Shao H.-Y., Lin H.-Y., Liu C.-C., Hsiao K.-N., Chitra E., Tsou Y.-L., Chang H.-W., Sia C. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS ONE. 2013;8:e57591. doi: 10.1371/journal.pone.0057591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo D., Yu X., Wang D., Li Z., Zhou Y., Xu G., Yuan B., Qin Y., Chen M. SLC35B2 acts in a dual role in the host sulfation required for EV71 infection. J. Virol. 2022;96:e02042-e21. doi: 10.1128/jvi.02042-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02042-21</ArticleId><ArticleId IdType="pmc">PMC9093107</ArticleId><ArticleId IdType="pubmed">35420441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynes R.O. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11–25. doi: 10.1016/0092-8674(92)90115-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(92)90115-S</ArticleId><ArticleId IdType="pubmed">1555235</ArticleId></ArticleIdList></Reference><Reference><Citation>Barczyk M., Carracedo S., Gullberg D. Integrins. Cell Tissue Res. 2010;339:269–280. doi: 10.1007/s00441-009-0834-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-009-0834-6</ArticleId><ArticleId IdType="pmc">PMC2784866</ArticleId><ArticleId IdType="pubmed">19693543</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaout M.A., Goodman S.L., Xiong J.P. Structure and mechanics of integrin-based cell adhesion. Curr. Opin. Cell Biol. 2007;19:495–507. doi: 10.1016/j.ceb.2007.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2007.08.002</ArticleId><ArticleId IdType="pmc">PMC2443699</ArticleId><ArticleId IdType="pubmed">17928215</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell I.D., Humphries M.J. Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol. 2011;3:a004994. doi: 10.1101/cshperspect.a004994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a004994</ArticleId><ArticleId IdType="pmc">PMC3039929</ArticleId><ArticleId IdType="pubmed">21421922</ArticleId></ArticleIdList></Reference><Reference><Citation>King S.L., Kamata T., Cunningham J.A., Emsley J., Liddington R.C., Takada Y., Bergelson J.M. Echovirus 1 interaction with the human very late antigen-2 (integrin alpha2beta1) I domain. Identification of two independent virus contact sites distinct from the metal ion-dependent adhesion site. J. Biol. Chem. 1997;272:28518–28522. doi: 10.1074/jbc.272.45.28518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.45.28518</ArticleId><ArticleId IdType="pubmed">9353313</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams C.H., Kajander T., Hyypia T., Jackson T., Sheppard D., Stanway G. Integrin alpha v beta 6 is an RGD-dependent receptor for coxsackievirus A9. J. Virol. 2004;78:6967–6973. doi: 10.1128/JVI.78.13.6967-6973.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.13.6967-6973.2004</ArticleId><ArticleId IdType="pmc">PMC421648</ArticleId><ArticleId IdType="pubmed">15194773</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafilou M., Wilson K.M., Triantafilou K. Identification of Echovirus 1 and coxsackievirus A9 receptor molecules via a novel flow cytometric quantification method. Cytometry. 2001;43:279–289. doi: 10.1002/1097-0320(20010401)43:4&lt;279::AID-CYTO1060&gt;3.0.CO;2-B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0320(20010401)43:4&lt;279::AID-CYTO1060&gt;3.0.CO;2-B</ArticleId><ArticleId IdType="pubmed">11260595</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bournonville S., Vangrunderbeeck S., Kerckhofs G. Contrast-Enhanced MicroCT for Virtual 3D Anatomical Pathology of Biological Tissues: A Literature Review. Contrast Media Mol. Imaging. 2019;2019:8617406. doi: 10.1155/2019/8617406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/8617406</ArticleId><ArticleId IdType="pmc">PMC6421764</ArticleId><ArticleId IdType="pubmed">30944550</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne C.B., Bergelson J.M. CAR: A virus receptor within the tight junction. Adv. Drug Deliv. Rev. 2005;57:869–882. doi: 10.1016/j.addr.2005.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2005.01.007</ArticleId><ArticleId IdType="pubmed">15820557</ArticleId></ArticleIdList></Reference><Reference><Citation>Raschperger E., Thyberg J., Pettersson S., Philipson L., Fuxe J., Pettersson R.F. The coxsackie- and adenovirus receptor (CAR) is an in vivo marker for epithelial tight junctions, with a potential role in regulating permeability and tissue homeostasis. Exp. Cell Res. 2006;312:1566–1580. doi: 10.1016/j.yexcr.2006.01.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2006.01.025</ArticleId><ArticleId IdType="pubmed">16542650</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomko R.P., Xu R., Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA. 1997;94:3352–3356. doi: 10.1073/pnas.94.7.3352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.7.3352</ArticleId><ArticleId IdType="pmc">PMC20373</ArticleId><ArticleId IdType="pubmed">9096397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis B.L., Potts P.R., Porteus M.H. Creating higher titer lentivirus with caffeine. Hum. Gene Ther. 2011;22:93–100. doi: 10.1089/hum.2010.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2010.068</ArticleId><ArticleId IdType="pmc">PMC3025180</ArticleId><ArticleId IdType="pubmed">20626321</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda T., Saitoh H., Masuko M., Katagiri-Abe T., Tominaga K., Kozakai I., Kobayashi K., Kumanishi T., Watanabe Y.D.G., Odani S., et al. The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. Mol. Brain Res. 2000;77:19–28. doi: 10.1016/S0169-328X(00)00036-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(00)00036-X</ArticleId><ArticleId IdType="pubmed">10814828</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotta Y., Honda T., Naito M., Kuwano R. Developmental distribution of coxsackie virus and adenovirus receptor localized in the nervous system. Brain Research. Dev. Brain Res. 2003;143:1–13. doi: 10.1016/S0165-3806(03)00035-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-3806(03)00035-X</ArticleId><ArticleId IdType="pubmed">12763576</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbantoglu J., Pari G., Karpati G., Holland P.M.C. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum. Gene Ther. 1999;10:1009–1019. doi: 10.1089/10430349950018409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/10430349950018409</ArticleId><ArticleId IdType="pubmed">10223734</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., Finberg R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320–1323. doi: 10.1126/science.275.5304.1320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.275.5304.1320</ArticleId><ArticleId IdType="pubmed">9036860</ArticleId></ArticleIdList></Reference><Reference><Citation>Raschperger E., Engstrom U., Pettersson R.F., Fuxe J. CLMP, a novel member of the CTX family and a new component of epithelial tight junctions. J. Biol. Chem. 2004;279:796–804. doi: 10.1074/jbc.M308249200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M308249200</ArticleId><ArticleId IdType="pubmed">14573622</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson S.D., Chapman N.N., Tracy S.M. Purification of the putative coxsackievirus B receptor from HeLa cells. Biochem. Biophys. Res. Commun. 1997;233:325–328. doi: 10.1006/bbrc.1997.6449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1997.6449</ArticleId><ArticleId IdType="pubmed">9144533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipatova A.V., Le T.H., Sosnovtseva A.O., Babaeva F.E., Kochetkov D.V., Chumakov P.M. Relationship between Cell Receptors and Tumor Cell Sensitivity to Oncolytic Enteroviruses. Bull. Exp. Biol. Med. 2018;166:58–62. doi: 10.1007/s10517-018-4289-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10517-018-4289-1</ArticleId><ArticleId IdType="pubmed">30450519</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafilou K., Triantafilou M. Lipid-raft-dependent Coxsackievirus B4 internalization and rapid targeting to the Golgi. Virology. 2004;326:6–19. doi: 10.1016/j.virol.2004.04.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.04.051</ArticleId><ArticleId IdType="pubmed">15262490</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung S.K., Kim J.Y., Kim I.B., Park S.I., Paek K.H., Nam J.H. Internalization and trafficking mechanisms of coxsackievirus B3 in HeLa cells. Virology. 2005;333:31–40. doi: 10.1016/j.virol.2004.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.12.010</ArticleId><ArticleId IdType="pubmed">15708590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lublin D.M., Atkinson J.P. Decay-accelerating factor: Biochemistry, molecular biology, and function. Annu. Rev. Immunol. 1989;7:35–58. doi: 10.1146/annurev.iy.07.040189.000343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.iy.07.040189.000343</ArticleId><ArticleId IdType="pubmed">2469439</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson-Weller A., Burge J., Fearon D.T., Weller P.F., Austen K.F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 1982;129:184–189. doi: 10.4049/jimmunol.129.1.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.129.1.184</ArticleId><ArticleId IdType="pubmed">6211481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukacik P., Roversi P., White J., Esser D., Smith G.P., Billington J., Williams P.A., Rudd P.M., Wormald M.R., Harvey D.J., et al. Complement regulation at the molecular level: The structure of decay-accelerating factor. Proc. Natl. Acad. Sci. USA. 2004;101:1279–1284. doi: 10.1073/pnas.0307200101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0307200101</ArticleId><ArticleId IdType="pmc">PMC337044</ArticleId><ArticleId IdType="pubmed">14734808</ArticleId></ArticleIdList></Reference><Reference><Citation>Low M.G. Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors. Biochem. J. 1987;244:1–13. doi: 10.1042/bj2440001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2440001</ArticleId><ArticleId IdType="pmc">PMC1147945</ArticleId><ArticleId IdType="pubmed">2959270</ArticleId></ArticleIdList></Reference><Reference><Citation>Koretz K., Bruderlein S., Henne C., Moller P. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br. J. Cancer. 1992;66:810–814. doi: 10.1038/bjc.1992.365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.1992.365</ArticleId><ArticleId IdType="pmc">PMC1977964</ArticleId><ArticleId IdType="pubmed">1384641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharti R., Dey G., Lin F., Lathia J., Reizes O. CD55 in cancer: Complementing functions in a non-canonical manner. Cancer Lett. 2022;551:215935. doi: 10.1016/j.canlet.2022.215935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2022.215935</ArticleId><ArticleId IdType="pmc">PMC11019835</ArticleId><ArticleId IdType="pubmed">36216147</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarkson N.A., Kaufman R., Lublin D.M., Ward T., Pipkin P.A., Minor P.D., Evans D.J., Almond J.W. Characterization of the echovirus 7 receptor: Domains of CD55 critical for virus binding. J. Virol. 1995;69:5497–5501. doi: 10.1128/jvi.69.9.5497-5501.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.69.9.5497-5501.1995</ArticleId><ArticleId IdType="pmc">PMC189399</ArticleId><ArticleId IdType="pubmed">7543583</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren D.R. Viral cell entry induced by cross-linked decay-accelerating factor. J. Virol. 1998;72:9407–9412. doi: 10.1128/JVI.72.11.9407-9412.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.72.11.9407-9412.1998</ArticleId><ArticleId IdType="pmc">PMC110371</ArticleId><ArticleId IdType="pubmed">9765499</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne C.B., Bergelson J.M. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell. 2006;124:119–131. doi: 10.1016/j.cell.2005.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.10.035</ArticleId><ArticleId IdType="pubmed">16413486</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart A.D., Eustace H.E., McKee T.A., Brown T.D. A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts. J. Virol. 2002;76:9307–9322. doi: 10.1128/JVI.76.18.9307-9322.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.18.9307-9322.2002</ArticleId><ArticleId IdType="pmc">PMC136471</ArticleId><ArticleId IdType="pubmed">12186914</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Yang Q., Liu C., Wang G., Song H., Shang G., Peng R., Qu X., Liu S., Cui Y., et al. Molecular basis of differential receptor usage for naturally occurring CD55-binding and -nonbinding coxsackievirus B3 strains. Proc. Natl. Acad. Sci. USA. 2022;119:e2118590119. doi: 10.1073/pnas.2118590119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2118590119</ArticleId><ArticleId IdType="pmc">PMC8794823</ArticleId><ArticleId IdType="pubmed">35046043</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen C.J., Shieh J.T., Pickles R.J., Okegawa T., Hsieh J.T., Bergelson J.M. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc. Natl. Acad. Sci. USA. 2001;98:15191–15196. doi: 10.1073/pnas.261452898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.261452898</ArticleId><ArticleId IdType="pmc">PMC65005</ArticleId><ArticleId IdType="pubmed">11734628</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T., Yamakawa M., Takahashi T. Expression of complement regulating factors in gastric cancer cells. Mol. Pathol. 2002;55:193–199. doi: 10.1136/mp.55.3.193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/mp.55.3.193</ArticleId><ArticleId IdType="pmc">PMC1187173</ArticleId><ArticleId IdType="pubmed">12032231</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartosch B., Vitelli A., Granier C., Goujon C., Dubuisson J., Pascale S., Scarselli E., Cortese R., Nicosia A., Cosset F.L. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 2003;278:41624–41630. doi: 10.1074/jbc.M305289200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M305289200</ArticleId><ArticleId IdType="pubmed">12913001</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Yang W., Shen L., Turner J.R., Coyne C.B., Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 2009;83:2011–2014. doi: 10.1128/JVI.01888-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01888-08</ArticleId><ArticleId IdType="pmc">PMC2643775</ArticleId><ArticleId IdType="pubmed">19052094</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe N.G., Johansson E.S., Au G., Lindberg A.M., Barry R.D., Shafren D.R. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection. J. Virol. 2004;78:1431–1439. doi: 10.1128/JVI.78.3.1431-1439.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.3.1431-1439.2004</ArticleId><ArticleId IdType="pmc">PMC321397</ArticleId><ArticleId IdType="pubmed">14722298</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson E.S., Xing L., Cheng R.H., Shafren D.R. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21. J. Virol. 2004;78:12603–12612. doi: 10.1128/JVI.78.22.12603-12612.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.22.12603-12612.2004</ArticleId><ArticleId IdType="pmc">PMC525059</ArticleId><ArticleId IdType="pubmed">15507647</ArticleId></ArticleIdList></Reference><Reference><Citation>Holla V.R., Wang D., Brown J.R., Mann J.R., Katkuri S., DuBois R.N. Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J. Biol. Chem. 2005;280:476–483. doi: 10.1074/jbc.M407403200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407403200</ArticleId><ArticleId IdType="pubmed">15520008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T., Nakamura T., Matsumoto K. The functions and possible significance of Kremen as the gatekeeper of Wnt signalling in development and pathology. J. Cell Mol. Med. 2008;12:391–408. doi: 10.1111/j.1582-4934.2007.00201.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2007.00201.x</ArticleId><ArticleId IdType="pmc">PMC3822531</ArticleId><ArticleId IdType="pubmed">18088386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T., Aoki S., Kitajima K., Takahashi T., Matsumoto K., Nakamura T. Molecular cloning and characterization of Kremen, a novel kringle-containing transmembrane protein. Biochim. Biophys. Acta (BBA)-Gene Struct. Expr. 2001;1518:63–72. doi: 10.1016/S0167-4781(01)00168-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-4781(01)00168-3</ArticleId><ArticleId IdType="pubmed">11267660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao B., Wu W., Davidson G., Marhold J., Li M., Mechler B.M., Delius H., Hoppe D., Stannek P., Walter C. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature. 2002;417:664–667. doi: 10.1038/nature756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature756</ArticleId><ArticleId IdType="pubmed">12050670</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero A., Romão M.J., Varela P.F., Kölln I., Dias J.M., Carvalho A.V.L., Sanz L., Töpfer-Petersen E., Calvete J.J. The crystal structures of two spermadhesins reveal the CUB domain fold. Nat. Struct. Biol. 1997;4:783–788. doi: 10.1038/nsb1097-783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsb1097-783</ArticleId><ArticleId IdType="pubmed">9334740</ArticleId></ArticleIdList></Reference><Reference><Citation>Verna J., Lodder A., Lee K., Vagts A., Ballester R. A family of genes required for maintenance of cell wall integrity and for the stress response in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA. 1997;94:13804–13809. doi: 10.1073/pnas.94.25.13804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.25.13804</ArticleId><ArticleId IdType="pmc">PMC28388</ArticleId><ArticleId IdType="pubmed">9391108</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y., Peng R., Song H., Tong Z., Qu X., Liu S., Zhao X., Chai Y., Wang P., Gao G.F., et al. Molecular basis of Coxsackievirus A10 entry using the two-in-one attachment and uncoating receptor KRM1. Proc. Natl. Acad. Sci. USA. 2020;117:18711–18718. doi: 10.1073/pnas.2005341117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005341117</ArticleId><ArticleId IdType="pmc">PMC7414063</ArticleId><ArticleId IdType="pubmed">32690697</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen J.T., Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: Implications for development of new diagnostics and therapeutics. Drug Metab. Pharmacokinet. 2009;24:318–332. doi: 10.2133/dmpk.24.318.</Citation><ArticleIdList><ArticleId IdType="doi">10.2133/dmpk.24.318</ArticleId><ArticleId IdType="pubmed">19745559</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker K., Rath T., Flak M.B., Arthur J.C., Chen Z., Glickman J.N., Zlobec I., Karamitopoulou E., Stachler M.D., Odze R.D., et al. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity. 2013;39:1095–1107. doi: 10.1016/j.immuni.2013.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.11.003</ArticleId><ArticleId IdType="pmc">PMC3902970</ArticleId><ArticleId IdType="pubmed">24290911</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Dong M., Wang X.G. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chin. Med. J. 2016;129:448–455. doi: 10.4103/0366-6999.176084.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.176084</ArticleId><ArticleId IdType="pmc">PMC4800846</ArticleId><ArticleId IdType="pubmed">26879019</ArticleId></ArticleIdList></Reference><Reference><Citation>Akilesh S., Christianson G.J., Roopenian D.O.C., Shaw A.S. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J. Immunol. 2007;179:4580–4588. doi: 10.4049/jimmunol.179.7.4580.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.7.4580</ArticleId><ArticleId IdType="pubmed">17878355</ArticleId></ArticleIdList></Reference><Reference><Citation>Sockolosky J.T., Szoka F.C. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv. Drug Deliv. Rev. 2015;91:109–124. doi: 10.1016/j.addr.2015.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2015.02.005</ArticleId><ArticleId IdType="pmc">PMC4544678</ArticleId><ArticleId IdType="pubmed">25703189</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldwin W.M., III, Valujskikh A., Fairchild R.L. The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals. Am. J. Transpl. 2019;19:1881–1887. doi: 10.1111/ajt.15366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15366</ArticleId><ArticleId IdType="pmc">PMC6591018</ArticleId><ArticleId IdType="pubmed">30903736</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyzik M., Rath T., Lencer W.I., Baker K., Blumberg R.S. FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J. Immunol. 2015;194:4595–4603. doi: 10.4049/jimmunol.1403014.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1403014</ArticleId><ArticleId IdType="pmc">PMC4451002</ArticleId><ArticleId IdType="pubmed">25934922</ArticleId></ArticleIdList></Reference><Reference><Citation>Simister N.E., Ahouse J.C. The structure and evolution of FcRn. Res. Immunol. 1996;147:333–337; discussion 353. doi: 10.1016/0923-2494(96)89647-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0923-2494(96)89647-7</ArticleId><ArticleId IdType="pubmed">8876062</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R., Zhang W., Shang X., Chen H., Mu X., Zhang Y., Zheng Q., Wang X., Liu Y. Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer. Front. Pharmacol. 2022;13:1013672. doi: 10.3389/fphar.2022.1013672.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1013672</ArticleId><ArticleId IdType="pmc">PMC9635818</ArticleId><ArticleId IdType="pubmed">36339597</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadena Castaneda D., Brachet G., Goupille C., Ouldamer L., Gouilleux-Gruart V. The neonatal Fc receptor in cancer FcRn in cancer. Cancer Med. 2020;9:4736–4742. doi: 10.1002/cam4.3067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3067</ArticleId><ArticleId IdType="pmc">PMC7333860</ArticleId><ArticleId IdType="pubmed">32368865</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Shannessy D.J., Bendas K., Schweizer C., Wang W., Albone E., Somers E.B., Weil S., Meredith R.K., Wustner J., Grasso L., et al. Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer. Genomics. 2017;109:251–257. doi: 10.1016/j.ygeno.2017.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2017.04.006</ArticleId><ArticleId IdType="pubmed">28450240</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalloneau E., Baroukh N., Mavridis K., Maillet A., Gueugnon F., Courty Y., Petit A., Kryza T., Del Rio M., Guyetant S., et al. Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis. Oncotarget. 2016;7:54415–54429. doi: 10.18632/oncotarget.10074.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.10074</ArticleId><ArticleId IdType="pmc">PMC5342352</ArticleId><ArticleId IdType="pubmed">27384673</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiercz R., Mo M., Khare P., Schneider Z., Ober R.J., Ward E.S. Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption. Oncotarget. 2017;8:3528–3541. doi: 10.18632/oncotarget.13869.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.13869</ArticleId><ArticleId IdType="pmc">PMC5356901</ArticleId><ArticleId IdType="pubmed">27974681</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaneda D.O.C., Dhommee C., Baranek T., Dalloneau E., Lajoie L., Valayer A., Arnoult C., Demattei M.V., Fouquenet D., Parent C., et al. Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment. Front. Immunol. 2018;9:2259. doi: 10.3389/fimmu.2018.02259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02259</ArticleId><ArticleId IdType="pmc">PMC6172308</ArticleId><ArticleId IdType="pubmed">30323819</ArticleId></ArticleIdList></Reference><Reference><Citation>Challa D.V.K., Wang X., Montoyo H.P., Velmurugan R., Ober R.J., Ward E.S. Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis. MAbs. 2019;11:848–860. doi: 10.1080/19420862.2019.1602459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2019.1602459</ArticleId><ArticleId IdType="pmc">PMC6601554</ArticleId><ArticleId IdType="pubmed">30964743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogesch P., Dudek S., van Zandbergen G., Waibler Z., Anzaghe M. The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies. Int. J. Mol. Sci. 2021;22:8947. doi: 10.3390/ijms22168947.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168947</ArticleId><ArticleId IdType="pmc">PMC8396266</ArticleId><ArticleId IdType="pubmed">34445651</ArticleId></ArticleIdList></Reference><Reference><Citation>Morosky S., Wells A.V.I., Lemon K., Evans A.S., Schamus S., Bakkenist C.J., Coyne C.B. The neonatal Fc receptor is a pan-echovirus receptor. Proc. Natl. Acad. Sci. USA. 2019;116:3758–3763. doi: 10.1073/pnas.1817341116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1817341116</ArticleId><ArticleId IdType="pmc">PMC6397586</ArticleId><ArticleId IdType="pubmed">30808762</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi O., Akira S. Innate immunity to virus infection. Immunological. Rev. 2009;227:75–86. doi: 10.1111/j.1600-065X.2008.00737.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2008.00737.x</ArticleId><ArticleId IdType="pmc">PMC5489343</ArticleId><ArticleId IdType="pubmed">19120477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T., Akira S. Innate immune recognition of viral infection. Nat. Immunol. 2006;7:131–137. doi: 10.1038/ni1303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1303</ArticleId><ArticleId IdType="pubmed">16424890</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi O., Akira S. Recognition of viruses by innate immunity. Immunol. Rev. 2007;220:214–224. doi: 10.1111/j.1600-065X.2007.00562.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2007.00562.x</ArticleId><ArticleId IdType="pubmed">17979849</ArticleId></ArticleIdList></Reference><Reference><Citation>Carty M., Guy C., Bowie A.G. Detection of Viral Infections by Innate Immunity. Biochem. Pharmacol. 2021;183:114316. doi: 10.1016/j.bcp.2020.114316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2020.114316</ArticleId><ArticleId IdType="pubmed">33152343</ArticleId></ArticleIdList></Reference><Reference><Citation>Barral P.M., Sarkar D., Su Z.z., Barber G.N., DeSalle R., Racaniello V.R., Fisher P.B. Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: Key regulators of innate immunity. Pharmacol. Ther. 2009;124:219–234. doi: 10.1016/j.pharmthera.2009.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2009.06.012</ArticleId><ArticleId IdType="pmc">PMC3165056</ArticleId><ArticleId IdType="pubmed">19615405</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehwinkel J., Gack M.U. RIG-I-like receptors: Their regulation and roles in RNA sensing. Nat. Rev. Immunol. 2020;20:537–551. doi: 10.1038/s41577-020-0288-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0288-3</ArticleId><ArticleId IdType="pmc">PMC7094958</ArticleId><ArticleId IdType="pubmed">32203325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K.R., Ling P. Interplays between Enterovirus A71 and the innate immune system. J. Biomed. Sci. 2019;26:95. doi: 10.1186/s12929-019-0596-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0596-8</ArticleId><ArticleId IdType="pmc">PMC6886175</ArticleId><ArticleId IdType="pubmed">31787104</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Lei C., Xu Z., Yang F., Liu H., Zhu Z., Li S., Liu X., Shu H., Zheng H. Foot-and-mouth disease virus non-structural protein 3A inhibits the interferon-β signaling pathway. Sci. Rep. 2016;6:21888. doi: 10.1038/srep21888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep21888</ArticleId><ArticleId IdType="pmc">PMC4756384</ArticleId><ArticleId IdType="pubmed">26883855</ArticleId></ArticleIdList></Reference><Reference><Citation>Elrick M.J., Pekosz A., Duggal P. Enterovirus D68 molecular and cellular biology and pathogenesis. J. Biol. Chem. 2021;296:100317. doi: 10.1016/j.jbc.2021.100317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100317</ArticleId><ArticleId IdType="pmc">PMC7949111</ArticleId><ArticleId IdType="pubmed">33484714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell A.M., Gale M. RIG-I in RNA virus recognition. Virology. 2015;479:110–121. doi: 10.1016/j.virol.2015.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2015.02.017</ArticleId><ArticleId IdType="pmc">PMC4424084</ArticleId><ArticleId IdType="pubmed">25749629</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahavandi-Parizi P., Kariminik A., Montazeri M. Retinoic acid-inducible gene 1 (RIG-1) and IFN-β promoter stimulator-1 (IPS-1) significantly down-regulated in the severe coronavirus disease 2019 (COVID-19) Mol. Biol. Rep. 2023;50:907–911. doi: 10.1007/s11033-022-07981-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-022-07981-2</ArticleId><ArticleId IdType="pmc">PMC9617601</ArticleId><ArticleId IdType="pubmed">36309611</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L.-G., Wang Y.-Y., Han K.-J., Li L.-Y., Zhai Z., Shu H.-B. VISA is an adapter protein required for virus-triggered IFN-β signaling. Mol. Cell. 2005;19:727–740. doi: 10.1016/j.molcel.2005.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2005.08.014</ArticleId><ArticleId IdType="pubmed">16153868</ArticleId></ArticleIdList></Reference><Reference><Citation>Barral P.M., Sarkar D., Fisher P.B., Racaniello V.R. RIG-I is cleaved during picornavirus infection. Virology. 2009;391:171–176. doi: 10.1016/j.virol.2009.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.045</ArticleId><ArticleId IdType="pmc">PMC2743091</ArticleId><ArticleId IdType="pubmed">19628239</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q., Langereis M.A., Lork M., Nguyen M., Hato S.V., Lanke K., Emdad L., Bhoopathi P., Fisher P.B., Lloyd R.E., et al. Enterovirus 2A pro Targets MDA5 and MAVS in Infected Cells. J. Virol. 2014;88:3369–3378. doi: 10.1128/JVI.02712-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02712-13</ArticleId><ArticleId IdType="pmc">PMC3957915</ArticleId><ArticleId IdType="pubmed">24390337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., Liu X., Ma Y., Sun Z., Yang Y., Jin Q., He B., Wang J. The 3C Protein of Enterovirus 71 Inhibits Retinoid Acid-Inducible Gene I-Mediated Interferon Regulatory Factor 3 Activation and Type I Interferon Responses. J. Virol. 2010;84:8051–8061. doi: 10.1128/JVI.02491-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02491-09</ArticleId><ArticleId IdType="pmc">PMC2916543</ArticleId><ArticleId IdType="pubmed">20519382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., Xiao X., Xue Q., Jin Q., He B., Wang J. Cleavage of Interferon Regulatory Factor 7 by Enterovirus 71 3C Suppresses Cellular Responses. J. Virol. 2013;87:1690–1698. doi: 10.1128/JVI.01855-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01855-12</ArticleId><ArticleId IdType="pmc">PMC3554134</ArticleId><ArticleId IdType="pubmed">23175366</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q., Langereis M.A., Olagnier D., Chiang C., van de Winkel R., van Essen P., Zoll J., Hiscott J., van Kuppeveld F.J.M. Coxsackievirus cloverleaf RNA containing a 5′ triphosphate triggers an antiviral response via RIG-I activation. PLoS ONE. 2014;9:e95927. doi: 10.1371/journal.pone.0095927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0095927</ArticleId><ArticleId IdType="pmc">PMC3997492</ArticleId><ArticleId IdType="pubmed">24759703</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Li M., Jia X., Deng H., Wang W., Wu F., Wang J., Dang S. Association of gene polymorphisms of pattern-recognition receptor signaling pathway with the risk and severity of hand, foot, and mouth disease caused by enterovirus 71 in Chinese Han population. J. Med. Virol. 2017;90:692–698. doi: 10.1002/jmv.25000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25000</ArticleId><ArticleId IdType="pubmed">29235129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang L., Gong X., Liu N., Xie G., Gao W., Kong G., Li X., Zhang J., Jin Y., Duan Z. A polymorphism in melanoma differentiation-associated gene 5 may be a risk factor for enterovirus 71 infection. Clin. Microbiol. Infect. 2014;20:O711–O717. doi: 10.1111/1469-0691.12618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12618</ArticleId><ArticleId IdType="pubmed">24621100</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshiumi H., Okamoto M., Fujii K., Kawanishi T., Matsumoto M., Koike S., Seya T. The TLR3/TICAM-1 pathway is mandatory for innate immune responses to poliovirus infection. J. Immunol. 2011;187:5320–5327. doi: 10.4049/jimmunol.1101503.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101503</ArticleId><ArticleId IdType="pubmed">21998457</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathinayake P.S., Hsu A.C.-Y., Wark P.A. Innate immunity and immune evasion by enterovirus 71. Viruses. 2015;7:6613–6630. doi: 10.3390/v7122961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122961</ArticleId><ArticleId IdType="pmc">PMC4690884</ArticleId><ArticleId IdType="pubmed">26694447</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., He X., Zheng Z., Zhang Z., Wei C., Guan K., Hou L., Zhang B., Zhu L., Cao Y., et al. Downregulation of MicroRNA miR-526a by Enterovirus Inhibits RIG-I-Dependent Innate Immune Response. J. Virol. 2014;88:11356–11368. doi: 10.1128/JVI.01400-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01400-14</ArticleId><ArticleId IdType="pmc">PMC4178780</ArticleId><ArticleId IdType="pubmed">25056901</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Xie Y., Li L., Li X., Shen L., Gong J., Zhang R. MicroRNA-30a Modulates Type I Interferon Responses to Facilitate Coxsackievirus B3 Replication Via Targeting Tripartite Motif Protein 25. Front. Immunol. 2021;11:603437. doi: 10.3389/fimmu.2020.603437.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.603437</ArticleId><ArticleId IdType="pmc">PMC7840606</ArticleId><ArticleId IdType="pubmed">33519812</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín-Vicente M., Medrano L.M., Resino S., García-Sastre A., Martínez I. TRIM25 in the regulation of the antiviral innate immunity. Front. Immunol. 2017;8:1187. doi: 10.3389/fimmu.2017.01187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01187</ArticleId><ArticleId IdType="pmc">PMC5614919</ArticleId><ArticleId IdType="pubmed">29018447</ArticleId></ArticleIdList></Reference><Reference><Citation>Gack M.U., Shin Y.C., Joo C.-H., Urano T., Liang C., Sun L., Takeuchi O., Akira S., Chen Z., Inoue S., et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007;446:916–920. doi: 10.1038/nature05732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05732</ArticleId><ArticleId IdType="pubmed">17392790</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth R.B., Sun L., Ea C.-K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3. Cell. 2005;122:669–682. doi: 10.1016/j.cell.2005.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.08.012</ArticleId><ArticleId IdType="pubmed">16125763</ArticleId></ArticleIdList></Reference><Reference><Citation>Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005;437:1167–1172. doi: 10.1038/nature04193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04193</ArticleId><ArticleId IdType="pubmed">16177806</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J.L., Coyne C.B. Mechanisms of MAVS regulation at the mitochondrial membrane. J. Mol. Biol. 2013;425:5009–5019. doi: 10.1016/j.jmb.2013.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2013.10.007</ArticleId><ArticleId IdType="pmc">PMC4562275</ArticleId><ArticleId IdType="pubmed">24120683</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda K., Takaoka A., Taniguchi T. Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors. Immunity. 2006;25:349–360. doi: 10.1016/j.immuni.2006.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.08.009</ArticleId><ArticleId IdType="pubmed">16979567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenoever B.R., Ng S.-L., Chua M.A., McWhirter S.M., García-Sastre A., Maniatis T. Multiple functions of the IKK-related kinase IKKε in interferon-mediated antiviral immunity. Science. 2007;315:1274–1278. doi: 10.1126/science.1136567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1136567</ArticleId><ArticleId IdType="pubmed">17332413</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J., Takeuchi O., Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 2005;6:981–988. doi: 10.1038/ni1243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1243</ArticleId><ArticleId IdType="pubmed">16127453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.O.C., Latz E., Golenbock D.T., Coyle A.J., Liao S.-M., Maniatis T. IKKE and TBKI are essential components of the IRF3 signaling pathway. Nat. Immunol. 2003;4:491–496. doi: 10.1038/ni921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni921</ArticleId><ArticleId IdType="pubmed">12692549</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang B., Li J., Zhang X., Zhao Q., Lu M., Lv Y. RIG-1 and MDA-5 signaling pathways contribute to IFN-β production and viral replication in porcine circovirus virus type 2-infected PK-15 cells in vitro. Vet. Microbiol. 2017;211:36–42. doi: 10.1016/j.vetmic.2017.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2017.09.022</ArticleId><ArticleId IdType="pubmed">29102119</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue B., Li H., Guo M., Wang J., Xu Y., Zou X., Deng R., Li G., Zhu H. TRIM21 Promotes Innate Immune Response to RNA Viral Infection through Lys27-Linked Polyubiquitination of MAVS. J. Virol. 2018;92:10–1128. doi: 10.1128/JVI.00321-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00321-18</ArticleId><ArticleId IdType="pmc">PMC6026736</ArticleId><ArticleId IdType="pubmed">29743353</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Li M., Song Y., Xu W. TRIM21 restricts coxsackievirus B3 replication, cardiac and pancreatic injury via interacting with MAVS and positively regulating IRF3-mediated Type-I interferon production. Front. Immunol. 2018;9:2479. doi: 10.3389/fimmu.2018.02479.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02479</ArticleId><ArticleId IdType="pmc">PMC6209670</ArticleId><ArticleId IdType="pubmed">30410495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopacinski A.B., Sweatt A.J., Smolko C.M., Gray-Gaillard E., Borgman C.A., Shah M., Janes K.A. Modeling the complete kinetics of coxsackievirus B3 reveals human determinants of host-cell feedback. Cell Syst. 2021;12:304–323.e13. doi: 10.1016/j.cels.2021.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2021.02.004</ArticleId><ArticleId IdType="pmc">PMC8112228</ArticleId><ArticleId IdType="pubmed">33740397</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q.-M., Song W.-Q., Li Y.-J., Qian J., Zhai A.-X., Wu J., Li A.-M., He J.-M., Zhao J.-Y., Yu X., et al. Over-expression of mitochondrial antiviral signaling protein inhibits coxsackievirus B3 infection by enhancing type-I interferons production. Virol. J. 2012;9:312. doi: 10.1186/1743-422X-9-312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-312</ArticleId><ArticleId IdType="pmc">PMC3546859</ArticleId><ArticleId IdType="pubmed">23249700</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Liu Y., Zheng Y., Tang Y., Zhu G., Qiu W., Huang L., Han S., Yin J., Peng B., et al. Autophagy triggered by MAVS inhibits Coxsackievirus A16 replication. Acta Virol. 2019;63:392–402. doi: 10.4149/av_2019_403.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/av_2019_403</ArticleId><ArticleId IdType="pubmed">31802682</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.-D., Sun L., Seth R.B., Pineda G., Chen Z.J. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. USA. 2005;102:17717–17722. doi: 10.1073/pnas.0508531102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0508531102</ArticleId><ArticleId IdType="pmc">PMC1308909</ArticleId><ArticleId IdType="pubmed">16301520</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Ma L., Stipkovits L., Szathmary S., Li X., Liu Y. The Strategy of Picornavirus Evading Host Antiviral Responses: Non-structural Proteins Suppress the Production of IFNs. Front. Microbiol. 2018;9:2943. doi: 10.3389/fmicb.2018.02943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.02943</ArticleId><ArticleId IdType="pmc">PMC6297142</ArticleId><ArticleId IdType="pubmed">30619109</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Yang E., Li X., Fan T., Guo S., Yang H., Wu B., Wang H. MAVS-Based Reporter Systems for Real-Time Imaging of EV71 Infection and Antiviral Testing. Viruses. 2023;15:1064. doi: 10.3390/v15051064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15051064</ArticleId><ArticleId IdType="pmc">PMC10220866</ArticleId><ArticleId IdType="pubmed">37243150</ArticleId></ArticleIdList></Reference><Reference><Citation>Varki A. Sialic acids in human health and disease. Trends Mol. Med. 2008;14:351–360. doi: 10.1016/j.molmed.2008.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2008.06.002</ArticleId><ArticleId IdType="pmc">PMC2553044</ArticleId><ArticleId IdType="pubmed">18606570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S. Sialic Acids and Sialoglycoconjugates in the Biology of Life, Health and Disease. Academic Press; Cambridge, MA, USA: 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/c2017-0-03986-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Varki A., Gagneux P. Multifarious roles of sialic acids in immunity. Ann. N.Y. Acad. Sci. 2012;1253:16–36. doi: 10.1111/j.1749-6632.2012.06517.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2012.06517.x</ArticleId><ArticleId IdType="pmc">PMC3357316</ArticleId><ArticleId IdType="pubmed">22524423</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters C.E., Carette J.E. Return of the neurotropic enteroviruses: Co-opting cellular pathways for infection. Viruses. 2021;13:166. doi: 10.3390/v13020166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020166</ArticleId><ArticleId IdType="pmc">PMC7911124</ArticleId><ArticleId IdType="pubmed">33499355</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld A.B., Warren A.V.L., Racaniello V.R. Neurotropism of enterovirus D68 isolates is independent of sialic acid and is not a recently acquired phenotype. mBio. 2019;10:e02370-e19. doi: 10.1128/mBio.02370-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02370-19</ArticleId><ArticleId IdType="pmc">PMC6805996</ArticleId><ArticleId IdType="pubmed">31641090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Hu X.-Y., Yu X.-F. Current understanding of human enterovirus D68. Viruses. 2019;11:490. doi: 10.3390/v11060490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11060490</ArticleId><ArticleId IdType="pmc">PMC6631698</ArticleId><ArticleId IdType="pubmed">31146373</ArticleId></ArticleIdList></Reference><Reference><Citation>Heida R., Bhide Y.C., Gasbarri M., Kocabiyik Ö., Stellacci F., Huckriede A.V.L., Hinrichs W.L., Frijlink H.W. Advances in the development of entry inhibitors for sialic-acid-targeting viruses. Drug Discov. Today. 2020;26:122–137. doi: 10.1016/j.drudis.2020.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2020.10.009</ArticleId><ArticleId IdType="pmc">PMC7577316</ArticleId><ArticleId IdType="pubmed">33099021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry N., Inoue H., Jamshidi F., Storm R.J., Oberste M.S., Arnberg N. Coxsackievirus A24 Variant Uses Sialic Acid-Containing O -Linked Glycoconjugates as Cellular Receptors on Human Ocular Cells. J. Virol. 2011;85:11283–11290. doi: 10.1128/JVI.05597-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05597-11</ArticleId><ArticleId IdType="pmc">PMC3194947</ArticleId><ArticleId IdType="pubmed">21880775</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander D.A., Dimock K. Sialic Acid Functions in Enterovirus 70 Binding and Infection. J. Virol. 2002;76:11265–11272. doi: 10.1128/JVI.76.22.11265-11272.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.22.11265-11272.2002</ArticleId><ArticleId IdType="pmc">PMC136758</ArticleId><ArticleId IdType="pubmed">12388686</ArticleId></ArticleIdList></Reference><Reference><Citation>Su P.-Y., Liu Y.-T., Chang H.-Y., Huang S.-W., Wang Y.-F., Yu C.-K., Wang J.-R., Chang C.-F. Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. BMC Microbiol. 2012;12:162. doi: 10.1186/1471-2180-12-162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-12-162</ArticleId><ArticleId IdType="pmc">PMC3478995</ArticleId><ArticleId IdType="pubmed">22853823</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrosovich M., Herrler G., Klenk H.D. Sialic acid receptors of viruses. Top. Curr. Chem. 2015;367:1–28. doi: 10.1007/128_2013_466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/128_2013_466</ArticleId><ArticleId IdType="pmc">PMC7120183</ArticleId><ArticleId IdType="pubmed">23873408</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomon R., Webster R.G. The Influenza Virus Enigma. Cell. 2009;136:402–410. doi: 10.1016/j.cell.2009.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.01.029</ArticleId><ArticleId IdType="pmc">PMC2971533</ArticleId><ArticleId IdType="pubmed">19203576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamiki H., Murakami S., Nishikaze T., Hiono T., Igarashi M., Furuse Y., Matsugo H., Ishida H., Katayama M., Sekine W., et al. Influenza A Virus Agnostic Receptor Tropism Revealed Using a Novel Biological System with Terminal Sialic Acid Knockout Cells. J. Virol. 2022;96:e0041622. doi: 10.1128/jvi.00416-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00416-22</ArticleId><ArticleId IdType="pmc">PMC9364805</ArticleId><ArticleId IdType="pubmed">35862707</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnaev I.I., Bocharnikova M.E., Afonnikov D.A. Human phospholipases A2: A functional and evolutionary analysis. Vavilovskii Zhurnal Genet. I Sel. 2022;26:787–797. doi: 10.18699/VJGB-22-95.</Citation><ArticleIdList><ArticleId IdType="doi">10.18699/VJGB-22-95</ArticleId><ArticleId IdType="pmc">PMC9837156</ArticleId><ArticleId IdType="pubmed">36694720</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton D.O.C. Phospholipases A2: Structure and function. Eur. J. Lipid Sci. Technol. 2005;107:193–205. doi: 10.1002/ejlt.200401089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejlt.200401089</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Liu Y., Lyoo H., van Vliet A.V.L.W., Wahedi M., de Bruin J.W., Roberts R.W., Overduin P., Meijer A., Rossmann M.G., et al. Bypassing pan-enterovirus host factor PLA2G16. Nat. Commun. 2019;10:1–10. doi: 10.1038/s41467-019-11256-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11256-z</ArticleId><ArticleId IdType="pmc">PMC6639302</ArticleId><ArticleId IdType="pubmed">31320648</ArticleId></ArticleIdList></Reference><Reference><Citation>Staring J., von Castelmur E., Blomen V.A., van den Hengel L.G., Brockmann M., Baggen J., Thibaut H.J., Nieuwenhuis J., Janssen H., van Kuppeveld F.J., et al. PLA2G16 represents a switch between entry and clearance of Picornaviridae. Nature. 2017;541:412–416. doi: 10.1038/nature21032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21032</ArticleId><ArticleId IdType="pubmed">28077878</ArticleId></ArticleIdList></Reference><Reference><Citation>Elling U., Wimmer R.A., Leibbrandt A., Burkard T., Michlits G., Leopoldi A., Micheler T., Abdeen D., Zhuk S., Aspalter I.M., et al. A reversible haploid mouse embryonic stem cell biobank resource for functional genomics. Nature. 2017;550:114–118. doi: 10.1038/nature24027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24027</ArticleId><ArticleId IdType="pmc">PMC6235111</ArticleId><ArticleId IdType="pubmed">28953874</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong S., Tu H., Kollareddy M., Pant V., Li Q., Zhang Y., Jackson J.G., Suh Y.-A., Elizondo-Fraire A.C., Yang P., et al. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc. Natl. Acad. Sci. USA. 2014;111:11145–11150. doi: 10.1073/pnas.1404139111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1404139111</ArticleId><ArticleId IdType="pmc">PMC4121829</ArticleId><ArticleId IdType="pubmed">25024203</ArticleId></ArticleIdList></Reference><Reference><Citation>The Human Protein Atlas.  [(accessed on 19 August 2024)].  Available online:  https://www.proteinatlas.org/</Citation></Reference><Reference><Citation>Uhlen M., Fagerberg L., Hallstrom B.M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson A., Kampf C., Sjostedt E., Asplund A., et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. doi: 10.1126/science.1260419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson D., Jarry A., Baury B., Blanchardie P., Laboisse C., Lustenberger P., Denis M.G. Overexpression of the CD155 gene in human colorectal carcinoma. Gut. 2001;49:236–240. doi: 10.1136/gut.49.2.236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.49.2.236</ArticleId><ArticleId IdType="pmc">PMC1728395</ArticleId><ArticleId IdType="pubmed">11454801</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami D., Matsuda K., Iwamoto H., Mitani Y., Mizumoto Y., Nakamura Y., Matsuzaki I., Iwamoto R., Takahashi Y., Kojima F., et al. Prognostic value of CD155/TIGIT expression in patients with colorectal cancer. PLoS ONE. 2022;17:e0265908. doi: 10.1371/journal.pone.0265908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0265908</ArticleId><ArticleId IdType="pmc">PMC8946673</ArticleId><ArticleId IdType="pubmed">35324958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan K.E., Eustace B.K., Stewart J.K., Zehetmeier C., Torella C., Simeone M., Roy J.E., Unger C., Louis D.N., Ilag L.L., et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 2004;4:73. doi: 10.1186/1471-2407-4-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-4-73</ArticleId><ArticleId IdType="pmc">PMC524493</ArticleId><ArticleId IdType="pubmed">15471548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H., Chen X., Mo S., Mao X., Chen J., Liu Y., Lu Z., Yu S., Chen J. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma. Theranostics. 2023;13:4601–4614. doi: 10.7150/thno.86547.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.86547</ArticleId><ArticleId IdType="pmc">PMC10465224</ArticleId><ArticleId IdType="pubmed">37649613</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyama R., Kanayama M., Mori M., Matsumiya H., Taira A., Shinohara S., Takenaka M., Yoneda K., Kuroda K., Tanaka F. CD155 expression and its clinical significance in non-small cell lung cancer. Oncol. Lett. 2022;23:166. doi: 10.3892/ol.2022.13286.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2022.13286</ArticleId><ArticleId IdType="pmc">PMC8988260</ArticleId><ArticleId IdType="pubmed">35414831</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Xu C., Guo T., Zhan S., Quan Q., Li M., Wang Z., Zhang X., Guo L., Cao L. Clinical significance of CD155 expression and correlation with cellular components of tumor microenvironment in gastric adenocarcinoma. Front. Immunol. 2023;14:1173524. doi: 10.3389/fimmu.2023.1173524.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1173524</ArticleId><ArticleId IdType="pmc">PMC10333512</ArticleId><ArticleId IdType="pubmed">37441080</ArticleId></ArticleIdList></Reference><Reference><Citation>Inozume T., Yaguchi T., Furuta J., Harada K., Kawakami Y., Shimada S. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. J. Investig. Dermatol. 2016;136:255–263. doi: 10.1038/JID.2015.404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/JID.2015.404</ArticleId><ArticleId IdType="pubmed">26763445</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C., Ye W., Hu J., Othmane B., Li H., Chen J., Zu X. A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer. Front. Oncol. 2021;11:660273. doi: 10.3389/fonc.2021.660273.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.660273</ArticleId><ArticleId IdType="pmc">PMC8210672</ArticleId><ArticleId IdType="pubmed">34150627</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D.W., Huang M., Lin X.S., Huang Q. CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. Onco. Targets Ther. 2017;10:3817–3825. doi: 10.2147/OTT.S141476.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S141476</ArticleId><ArticleId IdType="pmc">PMC5546808</ArticleId><ArticleId IdType="pubmed">28814880</ArticleId></ArticleIdList></Reference><Reference><Citation>Enloe B.M., Jay D.G. Inhibition of Necl-5 (CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity. J. Neurooncol. 2011;102:225–235. doi: 10.1007/s11060-010-0323-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-010-0323-5</ArticleId><ArticleId IdType="pubmed">20680398</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Matsumoto K., Amano N., Koguchi D., Shimura S., Hagiwara M., Shimizu Y., Ikeda M., Sato Y., Iwamura M. Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer. Cancers. 2022;14:1576. doi: 10.3390/cancers14061576.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14061576</ArticleId><ArticleId IdType="pmc">PMC8946612</ArticleId><ArticleId IdType="pubmed">35326727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Zhu Y., Wang Q., Kong Y., Sheng H., Guo J., Xu J., Dai B. Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis. Urol. Oncol. 2020;38:41.e11–41.e18. doi: 10.1016/j.urolonc.2019.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urolonc.2019.07.006</ArticleId><ArticleId IdType="pubmed">31383549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong H., Cheng R., Li X., Gao G., Jiang X., Cheng H., Zhou X., Zhao W. CD155 expression and its prognostic value in postoperative patients with breast cancer. Biomed. Pharmacother. 2019;115:108884. doi: 10.1016/j.biopha.2019.108884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.108884</ArticleId><ArticleId IdType="pubmed">31035013</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi-Manaka A., Okumura G., Ichioka E., Kiyomatsu H., Ikeda T., Bando H., Shibuya A., Shibuya K. High expression of soluble CD155 in estrogen receptor-negative breast cancer. Breast Cancer. 2020;27:92–99. doi: 10.1007/s12282-019-00999-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12282-019-00999-8</ArticleId><ArticleId IdType="pmc">PMC6954153</ArticleId><ArticleId IdType="pubmed">31372841</ArticleId></ArticleIdList></Reference><Reference><Citation>Solecki D.J., Gromeier M., Mueller S., Bernhardt G., Wimmer E. Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog. J. Biol. Chem. 2002;277:25697–25702. doi: 10.1074/jbc.M201378200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M201378200</ArticleId><ArticleId IdType="pubmed">11983699</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.M., Brown M., Dobrikova E., Ramaswamy V., Taylor M.D., McLendon R., Sanks J., Chandramohan V., Bigner D., Gromeier M. Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. J. Neuropathol. Exp. Neurol. 2018;77:696–702. doi: 10.1093/jnen/nly045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nly045</ArticleId><ArticleId IdType="pmc">PMC6044395</ArticleId><ArticleId IdType="pubmed">29878245</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., McLendon R., Sankey E., Kornahrens R., Lyne A.M., Cavalli F.M.G., McKay Z., Herndon J.E., II, Remke M., Picard D., et al. CD155 is a putative therapeutic target in medulloblastoma. Clin. Transl. Oncol. 2023;25:696–705. doi: 10.1007/s12094-022-02975-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12094-022-02975-9</ArticleId><ArticleId IdType="pubmed">36301489</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsudo K., Takada K., Kinoshita F., Hashinokuchi A., Nagano T., Akamine T., Kohno M., Takenaka T., Shimokawa M., Oda Y., et al. CD155 Expression in Early-Stage Lung Adenocarcinoma. Ann. Thorac. Surg. 2024 doi: 10.1016/j.athoracsur.2024.05.042. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2024.05.042</ArticleId><ArticleId IdType="pubmed">38901626</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi-Manaka A., Okumura G., Kojima H., Cho Y., Hirochika R., Bando H., Sato T., Yoshikawa H., Hara H., Shibuya A., et al. Increased Soluble CD155 in the Serum of Cancer Patients. PLoS ONE. 2016;11:e0152982. doi: 10.1371/journal.pone.0152982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0152982</ArticleId><ArticleId IdType="pmc">PMC4822883</ArticleId><ArticleId IdType="pubmed">27049654</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsumi S., Matsumine A., Toyoda H., Niimi R., Iino T., Sudo A. Prognostic significance of CD155 mRNA expression in soft tissue sarcomas. Oncol. Lett. 2013;5:1771–1776. doi: 10.3892/ol.2013.1280.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2013.1280</ArticleId><ArticleId IdType="pmc">PMC3701002</ArticleId><ArticleId IdType="pubmed">23833639</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan K.E., Stewart J.K., Treloar A.F., Matthews R.T., Jay D.G. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 2005;65:10930–10937. doi: 10.1158/0008-5472.CAN-05-1890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-05-1890</ArticleId><ArticleId IdType="pubmed">16322240</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiwada S., Sho M., Yasuda S., Shimada K., Yamato I., Akahori T., Kinoshita S., Nagai M., Konishi N., Nakajima Y. Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res. 2015;35:2287–2297.</Citation><ArticleIdList><ArticleId IdType="pubmed">25862891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K., Ma L., Feng L., Huang Z., Meng X., Yu J. CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus. Front. Mol. Biosci. 2020;7:608404. doi: 10.3389/fmolb.2020.608404.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.608404</ArticleId><ArticleId IdType="pmc">PMC7817973</ArticleId><ArticleId IdType="pubmed">33490104</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.H., Kim J.H., Kang K.W., Lee S.R., Park Y., Sung H.J., Kim B.S. PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma. Biomedicines. 2022;10:1099. doi: 10.3390/biomedicines10051099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10051099</ArticleId><ArticleId IdType="pmc">PMC9139015</ArticleId><ArticleId IdType="pubmed">35625835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q., Gao J., Yin P., Wang W., Wang B., Li Y., Zhao C. CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer. Cancer Sci. 2020;111:383–394. doi: 10.1111/cas.14276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.14276</ArticleId><ArticleId IdType="pmc">PMC7004517</ArticleId><ArticleId IdType="pubmed">31830330</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsten M., Norell H., Bryceson Y.T., Poschke I., Schedvins K., Ljunggren H.G., Kiessling R., Malmberg K.J. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J. Immunol. 2009;183:4921–4930. doi: 10.4049/jimmunol.0901226.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901226</ArticleId><ArticleId IdType="pubmed">19801517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepletier A., Madore J., O’Donnell J.S., Johnston R.L., Li X.Y., McDonald E., Ahern E., Kuchel A., Eastgate M., Pearson S.A., et al. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clin. Cancer Res. 2020;26:3671–3681. doi: 10.1158/1078-0432.CCR-19-3925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-19-3925</ArticleId><ArticleId IdType="pubmed">32345648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernek C.B. Avascular nonunion of a subtrochanteric femur fracture with formation of a heterotopic bone strut. Orthopedics. 1988;11:36–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">3353330</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev O., Kizner M., Roncato F., Dadiani M., Saini M., Castro-Giner F., Yajuk O., Kozlovski S., Levi N., Addadi Y., et al. ICAM-1 on Breast Cancer Cells Suppresses Lung Metastasis but Is Dispensable for Tumor Growth and Killing by Cytotoxic T Cells. Front. Immunol. 2022;13:849701. doi: 10.3389/fimmu.2022.849701.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.849701</ArticleId><ArticleId IdType="pmc">PMC9328178</ArticleId><ArticleId IdType="pubmed">35911772</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo P., Huang J., Wang L., Jia D., Yang J., Dillon D.A., Zurakowski D., Mao H., Moses M.A., Auguste D.T. ICAM-1 as a molecular target for triple negative breast cancer. Proc. Natl. Acad. Sci. USA. 2014;111:14710–14715. doi: 10.1073/pnas.1408556111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1408556111</ArticleId><ArticleId IdType="pmc">PMC4205631</ArticleId><ArticleId IdType="pubmed">25267626</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder C., Witzel I., Muller V., Krenkel S., Wirtz R.M., Janicke F., Schumacher U., Milde-Langosch K. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J. Cancer Res. Clin. Oncol. 2011;137:1193–1201. doi: 10.1007/s00432-011-0984-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00432-011-0984-2</ArticleId><ArticleId IdType="pubmed">21590495</ArticleId></ArticleIdList></Reference><Reference><Citation>Taftaf R., Liu X., Singh S., Jia Y., Dashzeveg N.K., Hoffmann A.D., El-Shennawy L., Ramos E.K., Adorno-Cruz V., Schuster E.J., et al. ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nat. Commun. 2021;12:4867. doi: 10.1038/s41467-021-25189-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25189-z</ArticleId><ArticleId IdType="pmc">PMC8358026</ArticleId><ArticleId IdType="pubmed">34381029</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L., Xia L., Zha B., Zuo C., Deng D., Chen M., Hu L., He Y., Dai F., Wu J., et al. miR-335-5p targeting ICAM-1 inhibits invasion and metastasis of thyroid cancer cells. Biomed. Pharmacother. 2018;106:983–990. doi: 10.1016/j.biopha.2018.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.07.046</ArticleId><ArticleId IdType="pubmed">30119270</ArticleId></ArticleIdList></Reference><Reference><Citation>Vedvyas Y., McCloskey J.E., Yang Y., Min I.M., Fahey T.J., Zarnegar R., Hsu Y.S., Hsu J.M., Van Besien K., Gaudet I., et al. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci. Rep. 2019;9:10634. doi: 10.1038/s41598-019-46938-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-46938-7</ArticleId><ArticleId IdType="pmc">PMC6650612</ArticleId><ArticleId IdType="pubmed">31337787</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitrago D., Keutgen X.M., Crowley M., Filicori F., Aldailami H., Hoda R., Liu Y.F., Hoda R.S., Scognamiglio T., Jin M., et al. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Ann. Surg. Oncol. 2012;19:973–980. doi: 10.1245/s10434-011-2029-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-011-2029-0</ArticleId><ArticleId IdType="pubmed">21879273</ArticleId></ArticleIdList></Reference><Reference><Citation>Song P., Xu Y., Ye G. B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma. Diagn. Pathol. 2024;19:77. doi: 10.1186/s13000-024-01504-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13000-024-01504-2</ArticleId><ArticleId IdType="pmc">PMC11163747</ArticleId><ArticleId IdType="pubmed">38858715</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X., Jiang J., Ye X., Liu Y., Wu Q., Wang L. Prognostic prediction and diagnostic role of intercellular adhesion molecule-1 (ICAM1) expression in clear cell renal cell carcinoma. J. Mol. Histol. 2014;45:427–434. doi: 10.1007/s10735-014-9568-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10735-014-9568-1</ArticleId><ArticleId IdType="pubmed">24535541</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruo Y., Gochi A., Kaihara A., Shimamura H., Yamada T., Tanaka N., Orita K. ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int. J. Cancer. 2002;100:486–490. doi: 10.1002/ijc.10514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.10514</ArticleId><ArticleId IdType="pubmed">12115535</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda K., Kang S.M., Sawada T., Nishiguchi Y., Yashiro M., Ogawa Y., Ohira M., Ishikawa T., Hirakawa Y.S.C.K. Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol. Rep. 2002;9:511–514. doi: 10.3892/or.9.3.511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.9.3.511</ArticleId><ArticleId IdType="pubmed">11956618</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarzycka M., Kotula-Balak M., Gil D. The mechanism of the contribution of ICAM-1 to epithelial-mesenchymal transition (EMT) in bladder cancer. Hum. Cell. 2024;37:801–816. doi: 10.1007/s13577-024-01053-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-024-01053-2</ArticleId><ArticleId IdType="pubmed">38519725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamai A., Meslin F., Benlalam H., Jalil A., Mehrpour M., Faure F., Lecluse Y., Vielh P., Avril M.F., Robert C., et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res. 2008;68:9854–9864. doi: 10.1158/0008-5472.CAN-08-0719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-08-0719</ArticleId><ArticleId IdType="pubmed">19047166</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell W.M., Rose-Zerilli M.J., Theaker J.M., Bateman A.C. ICAM-1 polymorphisms and development of cutaneous malignant melanoma. Int. J. Immunogenet. 2005;32:367–373. doi: 10.1111/j.1744-313X.2005.00539.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1744-313X.2005.00539.x</ArticleId><ArticleId IdType="pubmed">16313300</ArticleId></ArticleIdList></Reference><Reference><Citation>Usami Y., Ishida K., Sato S., Kishino M., Kiryu M., Ogawa Y., Okura M., Fukuda Y., Toyosawa S. Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. Int. J. Cancer. 2013;133:568–578. doi: 10.1002/ijc.28066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.28066</ArticleId><ArticleId IdType="pubmed">23364881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotteas E.A., Boulas P., Gkiozos I., Tsagkouli S., Tsoukalas G., Syrigos K.N. The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: Implications for disease progression and prognosis. Anticancer Res. 2014;34:4665–4672.</Citation><ArticleIdList><ArticleId IdType="pubmed">25202042</ArticleId></ArticleIdList></Reference><Reference><Citation>Relph K., Arif M., Pandha H., Annels N., Simpson G.R. Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21. Methods Mol. Biol. 2023;2684:319–327. doi: 10.1007/978-1-0716-3291-8_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-3291-8_20</ArticleId><ArticleId IdType="pubmed">37410244</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan M.C., Penfold P.L., King N.J., Billson F.A., Conway R.M. Immunoglobulin superfamily expression in primary retinoblastoma and retinoblastoma cell lines. Oncol. Res. 2002;13:103–111.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392158</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold J.M., Cummings M., Purdie D., Chenevix-Trench G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br. J. Cancer. 2001;85:1351–1358. doi: 10.1054/bjoc.2001.2075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/bjoc.2001.2075</ArticleId><ArticleId IdType="pmc">PMC2375262</ArticleId><ArticleId IdType="pubmed">11720474</ArticleId></ArticleIdList></Reference><Reference><Citation>Allende-Vega N., Marco Brualla J., Falvo P., Alexia C., Constantinides M., Fayd’herbe de Maudave A., Coenon L., Gitenay D., Mitola G., Massa P., et al. Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1) Sci. Rep. 2022;12:1341. doi: 10.1038/s41598-022-05470-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-05470-x</ArticleId><ArticleId IdType="pmc">PMC8789909</ArticleId><ArticleId IdType="pubmed">35079096</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.M., Chang Z.L., Liao Y.Y., Chou M.C., Tang C.H. IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma. Cancer Lett. 2013;328:135–143. doi: 10.1016/j.canlet.2012.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2012.08.029</ArticleId><ArticleId IdType="pubmed">22939995</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega M.A., Segui-Real B., Garcia J.A., Cales C., Rodriguez F., Vanderkerckhove J., Sandoval I.V. Cloning, sequencing, and expression of a cDNA encoding rat LIMP II, a novel 74-kDa lysosomal membrane protein related to the surface adhesion protein CD36. J. Biol. Chem. 1991;266:16818–16824. doi: 10.1016/S0021-9258(18)55375-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)55375-8</ArticleId><ArticleId IdType="pubmed">1715871</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo D., Vega M.A. Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family. J. Biol. Chem. 1993;268:18929–18935. doi: 10.1016/S0021-9258(17)46716-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)46716-0</ArticleId><ArticleId IdType="pubmed">7689561</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy J.V., Riddell D.R., Owen J.S. Human scavenger receptor class B type II (SR-BII) and cellular cholesterol efflux. Biochem. J. 2004;377:741–747. doi: 10.1042/bj20030307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj20030307</ArticleId><ArticleId IdType="pmc">PMC1223905</ArticleId><ArticleId IdType="pubmed">14570588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritsch A., Tancevski I., Schgoer W., Pfeifhofer C., Gander R., Eller P., Foeger B., Stanzl U., Patsch J.R. Molecular characterization of rabbit scavenger receptor class B types I and II: Portal to central vein gradient of expression in the liver. J. Lipid Res. 2004;45:214–222. doi: 10.1194/jlr.M300353-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M300353-JLR200</ArticleId><ArticleId IdType="pubmed">14595001</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove J., Huby T., Stamataki Z., Vanwolleghem T., Meuleman P., Farquhar M., Schwarz A., Moreau M., Owen J.S., Leroux-Roels G., et al. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J. Virol. 2007;81:3162–3169. doi: 10.1128/JVI.02356-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02356-06</ArticleId><ArticleId IdType="pmc">PMC1866051</ArticleId><ArticleId IdType="pubmed">17215280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Wang H., Sun Y., Qi M., Li W., Zhang Z., Zhang X.E., Cui Z. Enterovirus A71 Oncolysis of Malignant Gliomas. Mol. Ther. 2020;28:1533–1546. doi: 10.1016/j.ymthe.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.04.005</ArticleId><ArticleId IdType="pmc">PMC7264442</ArticleId><ArticleId IdType="pubmed">32304669</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Fang J., Shan J., Xu L., Wu Y., Lu B., Zhang X., Wang C., Sun P., Wang Q. SCARB2 associates with tumor-infiltrating neutrophils and predicts poor prognosis in breast cancer. Breast Cancer Res. Treat. 2024;207:15–24. doi: 10.1007/s10549-024-07401-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-024-07401-y</ArticleId><ArticleId IdType="pubmed">38914918</ArticleId></ArticleIdList></Reference><Reference><Citation>Montastruc M., Reiffers J., Stoppa A.M., Sotto J.J., Corront B., Marit G., Maraninchi D., Michallet M., Gastaut J.A., Broustet A., et al. Treatment of acute myeloid leukemia in elderly patients: The influence of maintenance therapy (BGM 84 protocol) Nouv. Rev. Fr. Hematol. 1990;32:147–152.</Citation><ArticleIdList><ArticleId IdType="pubmed">2198531</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeh M., Bockhorn M., Gorgens D., Vieth M., Hoffmann T., Simon R., Izbicki J.R., Sauter G., Schumacher U., Anders M. Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: A multitumour array analysis. Br. J. Cancer. 2013;109:1848–1858. doi: 10.1038/bjc.2013.509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2013.509</ArticleId><ArticleId IdType="pmc">PMC3790165</ArticleId><ArticleId IdType="pubmed">24022195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeimet A.G., Muller-Holzner E., Schuler A., Hartung G., Berger J., Hermann M., Widschwendter M., Bergelson J.M., Marth C. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther. 2002;9:1093–1100. doi: 10.1038/sj.gt.3301775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3301775</ArticleId><ArticleId IdType="pubmed">12140737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasenburg A., Fischer D.O.C., Tong X.W., Rojas-Martinez A., Kaufman R.H., Ramzy I., Kohlberger P., Orlowska-Volk M., Aguilar-Cordova E., Kieback D.G. Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: Expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5. J. Soc. Gynecol. Investig. 2002;9:174–180. doi: 10.1177/107155760200900310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/107155760200900310</ArticleId><ArticleId IdType="pubmed">12009393</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimer D., Steppan I., Wiedemair A., Concin N., Hofstetter G., Marth C., Muller-Holzner E., Zeimet A.G. Soluble isoforms but not the transmembrane form of coxsackie-adenovirus receptor are of clinical relevance in epithelial ovarian cancer. Int. J. Cancer. 2007;120:2568–2575. doi: 10.1002/ijc.22580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.22580</ArticleId><ArticleId IdType="pubmed">17278108</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin M., Escuadro B., Dohadwala M., Sharma S., Batra R.K. A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cells. Cancer Res. 2004;64:6377–6380. doi: 10.1158/0008-5472.CAN-04-1490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-04-1490</ArticleId><ArticleId IdType="pubmed">15374942</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Wang S., Bao Y., Ni C., Guan N., Zhao J., Salford L.G., Widegren B., Fan X. Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers. J. Mol. Histol. 2006;37:153–160. doi: 10.1007/s10735-006-9055-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10735-006-9055-4</ArticleId><ArticleId IdType="pubmed">17031523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Fang B., Mohan R., Chang J.Y. Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiother. Oncol. 2012;105:250–257. doi: 10.1016/j.radonc.2012.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2012.09.002</ArticleId><ArticleId IdType="pmc">PMC3845342</ArticleId><ArticleId IdType="pubmed">23022172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunder T., Schmid K., Wicklein D., Groitl P., Dobner T., Lange T., Anders M., Schumacher U. Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection. Cancer Gene Ther. 2013;20:25–32. doi: 10.1038/cgt.2012.80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cgt.2012.80</ArticleId><ArticleId IdType="pubmed">23196273</ArticleId></ArticleIdList></Reference><Reference><Citation>Uotani K., Tazawa H., Hasei J., Fujiwara T., Yoshida A., Yamakawa Y., Omori T., Sugiu K., Komatsubara T., Kondo H., et al. Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus. PLoS ONE. 2024;19:e0298292. doi: 10.1371/journal.pone.0298292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0298292</ArticleId><ArticleId IdType="pmc">PMC10878518</ArticleId><ArticleId IdType="pubmed">38377118</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaginis C., Zarros A., Alexandrou P., Klijanienko J., Delladetsima I., Theocharis S. Evaluation of coxsackievirus and adenovirus receptor expression in human benign and malignant thyroid lesions. APMIS. 2010;118:210–221. doi: 10.1111/j.1600-0463.2009.02582.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0463.2009.02582.x</ArticleId><ArticleId IdType="pubmed">20132187</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauen K.A., Sudilovsky D., Le J.L., Chew K.L., Hann B., Weinberg V., Schmitt L.D., McCormick F. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res. 2002;62:3812–3818.</Citation><ArticleIdList><ArticleId IdType="pubmed">12097294</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandha H.S., Stockwin L.T.H., Eaton J., Clarke I.A., Dalgleish A.G., Todryk S.M., Blair G.E. Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: Implications for gene therapy strategies. Prostate Cancer Prostatic. Dis. 2003;6:6–11. doi: 10.1038/sj.pcan.4500611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.pcan.4500611</ArticleId><ArticleId IdType="pubmed">12664058</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin T.A., Watkins G., Jiang W.G. The Coxsackie-adenovirus receptor has elevated expression in human breast cancer. Clin. Exp. Med. 2005;5:122–128. doi: 10.1007/s10238-005-0076-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-005-0076-1</ArticleId><ArticleId IdType="pubmed">16284735</ArticleId></ArticleIdList></Reference><Reference><Citation>Auer D., Reimer D., Porto V., Fleischer M., Roessler J., Wiedemair A., Marth C., Muller-Holzner E., Daxenbichler G., Zeimet A.G. Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer. Breast Cancer Res. Treat. 2009;116:103–111. doi: 10.1007/s10549-008-0108-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-008-0108-0</ArticleId><ArticleId IdType="pubmed">18618240</ArticleId></ArticleIdList></Reference><Reference><Citation>Vindrieux D., Le Corre L., Hsieh J.T., Metivier R., Escobar P., Caicedo A., Brigitte M., Lazennec G. Coxsackie and adenovirus receptor is a target and a mediator of estrogen action in breast cancer. Endocr. Relat. Cancer. 2011;18:311–321. doi: 10.1530/ERC-10-0230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERC-10-0230</ArticleId><ArticleId IdType="pubmed">21389059</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu W., Ogose A., Kawashima H., Ito M., Ito T., Matsuba A., Kitahara H., Hotta T., Tokunaga K., Hatano H., et al. High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing’s sarcoma, and benign neurogenic tumors among musculoskeletal tumors. Clin. Cancer Res. 2004;10:3831–3838. doi: 10.1158/1078-0432.CCR-03-0345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-03-0345</ArticleId><ArticleId IdType="pubmed">15173092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima H., Ogose A., Yoshizawa T., Kuwano R., Hotta Y., Hotta T., Hatano H., Kawashima H., Endo N. Expression of the coxsackievirus and adenovirus receptor in musculoskeletal tumors and mesenchymal tissues: Efficacy of adenoviral gene therapy for osteosarcoma. Cancer Sci. 2003;94:70–75. doi: 10.1111/j.1349-7006.2003.tb01354.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2003.tb01354.x</ArticleId><ArticleId IdType="pmc">PMC11160042</ArticleId><ArticleId IdType="pubmed">12708477</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice A.M., Currier M.A., Adams L.C., Bharatan N.S., Collins M.H., Snyder J.D., Khan J., Cripe T.P. Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis. J. Pediatr. Hematol. Oncol. 2002;24:527–533. doi: 10.1097/00043426-200210000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00043426-200210000-00006</ArticleId><ArticleId IdType="pubmed">12368688</ArticleId></ArticleIdList></Reference><Reference><Citation>Witlox M.A., Van Beusechem V.W., Grill J., Haisma H.J., Schaap G., Bras J., Van Diest P., De Gast A., Curiel D.T., Pinedo H.M., et al. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J. Gene Med. 2002;4:510–516. doi: 10.1002/jgm.308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgm.308</ArticleId><ArticleId IdType="pubmed">12221644</ArticleId></ArticleIdList></Reference><Reference><Citation>Galetke W., Randerath W., Feldmeyer F., David M., Trappe A., Ingenabel F. Importance of routine examinations in patients with obstructive sleep apnea syndrome. Pneumologie. 2002;56:432–437. doi: 10.1055/s-2002-32871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2002-32871</ArticleId><ArticleId IdType="pubmed">12140797</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaginis C.T., Zarros A.C., Papaefthymiou M.A., Papadopouli A.E., Sfiniadakis I.K., Theocharis S.E. Coxsackievirus and adenovirus receptor expression in human endometrial adenocarcinoma: Possible clinical implications. World J. Surg. Oncol. 2008;6:59. doi: 10.1186/1477-7819-6-59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7819-6-59</ArticleId><ArticleId IdType="pmc">PMC2440381</ArticleId><ArticleId IdType="pubmed">18558015</ArticleId></ArticleIdList></Reference><Reference><Citation>Jee Y.S., Lee S.G., Lee J.C., Kim M.J., Lee J.J., Kim D.Y., Park S.W., Sung M.W., Heo D.S. Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res. 2002;22:2629–2634.</Citation><ArticleIdList><ArticleId IdType="pubmed">12529974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunder T., Schumacher U., Friedrich R.E. Coxsackie adenovirus receptor expression in carcinomas of the head and neck. Anticancer Res. 2012;32:1057–1062.</Citation><ArticleIdList><ArticleId IdType="pubmed">22399632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal R.M., Sharma S., Gardner B.K., Douglas J.T., Bergelson J.M., Dubinett S.M., Batra R.K. Soluble coxsackievirus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu. Clin. Cancer Res. 2002;8:1915–1923.</Citation><ArticleIdList><ArticleId IdType="pubmed">12060636</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs M.D., Rauen K.A., Ramamurthy M., Dodson J.L., De Marzo A.M., Putzi M.J., Schoenberg M.P., Rodriguez R. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology. 2002;60:531–536. doi: 10.1016/S0090-4295(02)01748-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-4295(02)01748-X</ArticleId><ArticleId IdType="pubmed">12350512</ArticleId></ArticleIdList></Reference><Reference><Citation>Buscarini M., Quek M.L., Gilliam-Hegarich S., Kasahara N., Bochner B. Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. Urol. Int. 2007;78:160–166. doi: 10.1159/000098076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000098076</ArticleId><ArticleId IdType="pubmed">17293658</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn W.M., Macal M., Christian C., Lacher M.D., McMillan A., Rauen K.A., Warren R.S., Ferrell L. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther. 2006;13:792–797. doi: 10.1038/sj.cgt.7700947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cgt.7700947</ArticleId><ArticleId IdType="pubmed">16628228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino I., Matsubara H., Akutsu Y., Nishimori T., Yoneyama Y., Murakami K., Sakata H., Matsushita K., Komatsu A., Brooks R., et al. Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer. Anticancer Res. 2008;28:665–671.</Citation><ArticleIdList><ArticleId IdType="pubmed">18507005</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders M., Vieth M., Rocken C., Ebert M., Pross M., Gretschel S., Schlag P.M., Wiedenmann B., Kemmner W., Hocker M. Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression. Br. J. Cancer. 2009;100:352–359. doi: 10.1038/sj.bjc.6604876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6604876</ArticleId><ArticleId IdType="pmc">PMC2634721</ArticleId><ArticleId IdType="pubmed">19142187</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Li S., Wang H., Chen W., Mou X., Wang S. Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients. Oncol. Lett. 2019;17:2485–2490. doi: 10.3892/ol.2018.9868.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2018.9868</ArticleId><ArticleId IdType="pmc">PMC6350183</ArticleId><ArticleId IdType="pubmed">30719117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y.Y., Wang X.J., Han Y., Li G., Wang H.J., Wang S.B., Chen X.Y., Liu F.L., He X.L., Tong X.M., et al. Loss of coxsackie and adenovirus receptor expression in human colorectal cancer: A potential impact on the efficacy of adenovirus-mediated gene therapy in Chinese Han population. Mol. Med. Rep. 2016;14:2541–2547. doi: 10.3892/mmr.2016.5536.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2016.5536</ArticleId><ArticleId IdType="pmc">PMC4991754</ArticleId><ArticleId IdType="pubmed">27485384</ArticleId></ArticleIdList></Reference><Reference><Citation>Stecker K., Vieth M., Koschel A., Wiedenmann B., Rocken C., Anders M. Impact of the coxsackievirus and adenovirus receptor on the adenoma-carcinoma sequence of colon cancer. Br. J. Cancer. 2011;104:1426–1433. doi: 10.1038/bjc.2011.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2011.116</ArticleId><ArticleId IdType="pmc">PMC3101933</ArticleId><ArticleId IdType="pubmed">21468049</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders M., Rosch T., Kuster K., Becker I., Hofler H., Stein H.J., Meining A., Wiedenmann B., Sarbia M. Expression and function of the coxsackie and adenovirus receptor in Barrett’s esophagus and associated neoplasia. Cancer Gene Ther. 2009;16:508–515. doi: 10.1038/cgt.2008.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cgt.2008.103</ArticleId><ArticleId IdType="pubmed">19132065</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuxe J., Liu L., Malin S., Philipson L., Collins V.P., Pettersson R.F. Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int. J. Cancer. 2003;103:723–729. doi: 10.1002/ijc.10891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.10891</ArticleId><ArticleId IdType="pubmed">12516090</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Pong R.C., Bergelson J.M., Hall M.C., Sagalowsky A.V.I., Tseng C.P., Wang Z., Hsieh J.T. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 1999;59:325–330.</Citation><ArticleIdList><ArticleId IdType="pubmed">9927041</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto K., Shariat S.F., Ayala G.E., Rauen K.A., Lerner S.P. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology. 2005;66:441–446. doi: 10.1016/j.urology.2005.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2005.02.033</ArticleId><ArticleId IdType="pubmed">16040097</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K.C., Altinoz M., Wosik K., Larochelle N., Koty Z., Zhu L., Holland P.M.C., Nalbantoglu J. Impact of the coxsackie and adenovirus receptor (CAR) on glioma cell growth and invasion: Requirement for the C-terminal domain. Int. J. Cancer. 2005;113:738–745. doi: 10.1002/ijc.20623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.20623</ArticleId><ArticleId IdType="pubmed">15499626</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaoka K., Tada M., Sawamura Y., Ikeda J., Abe H. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J. Neurosurg. 2000;92:1002–1008. doi: 10.3171/jns.2000.92.6.1002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.2000.92.6.1002</ArticleId><ArticleId IdType="pubmed">10839262</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita M., Ino A., Kawabata K., Sakurai F., Mizuguchi H. Expression of coxsackie and adenovirus receptor reduces the lung metastatic potential of murine tumor cells. Int. J. Cancer. 2007;121:1690–1696. doi: 10.1002/ijc.22852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.22852</ArticleId><ArticleId IdType="pubmed">17546646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuster K., Grotzinger C., Koschel A., Fischer A., Wiedenmann B., Anders M. Sodium butyrate increases expression of the coxsackie and adenovirus receptor in colon cancer cells. Cancer Investig. 2010;28:268–274. doi: 10.3109/07357900902783195.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07357900902783195</ArticleId><ArticleId IdType="pubmed">19863349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuster K., Koschel A., Rohwer N., Fischer A., Wiedenmann B., Anders M. Downregulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1alpha. Cancer Gene Ther. 2010;17:141–146. doi: 10.1038/cgt.2009.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cgt.2009.49</ArticleId><ArticleId IdType="pubmed">19590529</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruning A., Runnebaum I.B. CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFalpha, and TGFbeta. Gene Ther. 2003;10:198–205. doi: 10.1038/sj.gt.3301887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3301887</ArticleId><ArticleId IdType="pubmed">12571626</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsteinsson L., O’Dowd G.M., Harrington P.M., Johnson P.M. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS. 1998;106:869–878. doi: 10.1111/j.1699-0463.1998.tb00233.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1699-0463.1998.tb00233.x</ArticleId><ArticleId IdType="pubmed">9808413</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller O.B., Moretto G., Kim S.U., Morgan B.P., Devine D.V. Complement expression on astrocytes and astrocytoma cell lines: Failure of complement regulation at the C3 level correlates with very low CD55 expression. J. Neuroimmunol. 1996;71:97–106. doi: 10.1016/S0165-5728(96)00136-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(96)00136-1</ArticleId><ArticleId IdType="pubmed">8982108</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinoura N., Heffelfinger S.C., Miller M., Shamraj O.I., Miura N.H., Larson J.J., DeTribolet N., Warnick R.E., Tew J.J., Menon A.G. RNA expression of complement regulatory proteins in human brain tumors. Cancer Lett. 1994;86:143–149. doi: 10.1016/0304-3835(94)90072-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3835(94)90072-8</ArticleId><ArticleId IdType="pubmed">7526972</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P., Thomas A., Fontaine M., Morgan B.P. Complement activation on human neuroblastoma cell lines in vitro: Route of activation and expression of functional complement regulatory proteins. J. Neuroimmunol. 1996;66:29–40. doi: 10.1016/0165-5728(96)00015-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(96)00015-X</ArticleId><ArticleId IdType="pubmed">8964911</ArticleId></ArticleIdList></Reference><Reference><Citation>Maenpaa A., Junnikkala S., Hakulinen J., Timonen T., Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am. J. Pathol. 1996;148:1139–1152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861510</ArticleId><ArticleId IdType="pubmed">8644856</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda H., Seya T., Hara T., Matsumoto M., Kinoshita T., Masaoka T. Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin’s lymphoma. Immunol. Lett. 1991;29:205–209. doi: 10.1016/0165-2478(91)90171-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-2478(91)90171-6</ArticleId><ArticleId IdType="pubmed">1722775</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T., Kojima A., Fukuda H., Masaoka T., Fukumori Y., Matsumoto M., Seya T. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br. J. Haematol. 1992;82:368–373. doi: 10.1111/j.1365-2141.1992.tb06431.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1992.tb06431.x</ArticleId><ArticleId IdType="pubmed">1384649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuraya M., Yefenof E., Klein G., Klein E. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: Their role in sensitivity to human serum-mediated lysis. Eur. J. Immunol. 1992;22:1871–1876. doi: 10.1002/eji.1830220729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830220729</ArticleId><ArticleId IdType="pubmed">1378022</ArticleId></ArticleIdList></Reference><Reference><Citation>Guc D., Canpinar H., Kucukaksu C., Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur. J. Haematol. 2000;64:3–9. doi: 10.1034/j.1600-0609.2000.80097.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0609.2000.80097.x</ArticleId><ArticleId IdType="pubmed">10680700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomstein Y., Fishelson Z. Enhanced sensitivity of P-glycoprotein-positive multidrug resistant tumor cells to complement-mediated lysis. Eur. J. Haematol. 1997;27:2204–2211. doi: 10.1002/eji.1830270913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830270913</ArticleId><ArticleId IdType="pubmed">9341760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraoka S., Mizuno M., Nasu J., Okazaki H., Makidono C., Okada H., Terada R., Yamamoto K., Fujita T., Shiratori Y. Enhanced expression of decay-accelerating factor, a complement-regulatory protein, in the specialized intestinal metaplasia of Barrett’s esophagus. J. Lab. Clin. Med. 2004;143:201–206. doi: 10.1016/j.lab.2003.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lab.2003.12.013</ArticleId><ArticleId IdType="pubmed">15085078</ArticleId></ArticleIdList></Reference><Reference><Citation>Murao T., Shiotani A., Fujita Y., Yamanaka Y., Kamada T., Manabe N., Hata J., Nishio K., Haruma K. Overexpression of CD55 from Barrett’s esophagus is associated with esophageal adenocarcinoma risk. J. Gastroenterol. Hepatol. 2016;31:99–106. doi: 10.1111/jgh.13055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13055</ArticleId><ArticleId IdType="pubmed">26202380</ArticleId></ArticleIdList></Reference><Reference><Citation>Juhl H., Helmig F., Baltzer K., Kalthoff H., Henne-Bruns D., Kremer B. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J. Surg. Oncol. 1997;64:222–230. doi: 10.1002/(SICI)1096-9098(199703)64:3&lt;222::AID-JSO9&gt;3.0.CO;2-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9098(199703)64:3&lt;222::AID-JSO9&gt;3.0.CO;2-C</ArticleId><ArticleId IdType="pubmed">9121154</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z., Wu H., Jiao Y., Zheng J. Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer. Oncol. Lett. 2015;9:793–797. doi: 10.3892/ol.2014.2751.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2014.2751</ArticleId><ArticleId IdType="pmc">PMC4301556</ArticleId><ArticleId IdType="pubmed">25624904</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Chen L., Peng S., Chen Z., Gimm O., Finke R., Hoang-Vu C. The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol. Rep. 2005;14:1413–1420. doi: 10.3892/or.14.6.1413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.14.6.1413</ArticleId><ArticleId IdType="pubmed">16273233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosch S.B., Scheunemann P., Luth M., Inndorf S., Stoecklein N.H., Erbersdobler A., Rehders A., Gundlach M., Knoefel W.T., Izbicki J.R. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer. J. Gastrointest. Surg. 2001;5:673–679. doi: 10.1016/S1091-255X(01)80111-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1091-255X(01)80111-6</ArticleId><ArticleId IdType="pubmed">12086907</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y., Chai N., Gu Y., Ding L., Yang Y., Zhou J., Ren G., Hao X., Fan D., Wu K., et al. Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer. Arch. Pathol. Lab. Med. 2014;138:910–919. doi: 10.5858/arpa.2013-0064-OA.</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2013-0064-OA</ArticleId><ArticleId IdType="pubmed">24978917</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Spendlove I., Morgan J., Durrant L.G. CD55 is over-expressed in the tumour environment. Br. J. Cancer. 2001;84:80–86. doi: 10.1054/bjoc.2000.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/bjoc.2000.1570</ArticleId><ArticleId IdType="pmc">PMC2363604</ArticleId><ArticleId IdType="pubmed">11139317</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Z.W., Liu M.C., Hong H.J., Du Q., Chen Y.L. Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. Tumor Biol. 2017;39:1010428317694319. doi: 10.1177/1010428317694319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1010428317694319</ArticleId><ArticleId IdType="pubmed">28345461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Lei L., Wang S., Gu D., Zhang J. Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma. J. Biomed. Biotechnol. 2012;2012:587672. doi: 10.1155/2012/587672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/587672</ArticleId><ArticleId IdType="pmc">PMC3324160</ArticleId><ArticleId IdType="pubmed">22547928</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafa T., Eckert A., Klonisch T., Kehlen A., Maurer P., Klintschar M., Erhuma M., Zschoyan R., Gimm O., Dralle H., et al. Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol. Biomark. Prev. 2005;14:108–119. doi: 10.1158/1055-9965.108.14.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.108.14.1</ArticleId><ArticleId IdType="pubmed">15668483</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukri A., Hanafiah A., Kosai N.R., Mohammed Taher M., Mohamed R. New insight on the role of Helicobacter pylori cagA in the expression of cell surface antigens with important biological functions in gastric carcinogenesis. Helicobacter. 2022;27:e12913. doi: 10.1111/hel.12913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12913</ArticleId><ArticleId IdType="pubmed">35848223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko K., Zaitoun A.M., Letley D.P., Rhead J.L., Torres J., Spendlove I., Atherton J.C., Robinson K. The active form of Helicobacter pylori vacuolating cytotoxin induces decay-accelerating factor CD55 in association with intestinal metaplasia in the human gastric mucosa. J. Pathol. 2022;258:199–209. doi: 10.1002/path.5990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5990</ArticleId><ArticleId IdType="pmc">PMC9543990</ArticleId><ArticleId IdType="pubmed">35851954</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakawa M., Yamada K., Tsuge T., Ohrui H., Ogata T., Dobashi M., Imai Y. Protection of thyroid cancer cells by complement-regulatory factors. Cancer. 1994;73:2808–2817. doi: 10.1002/1097-0142(19940601)73:11&lt;2808::AID-CNCR2820731125&gt;3.0.CO;2-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(19940601)73:11&lt;2808::AID-CNCR2820731125&gt;3.0.CO;2-P</ArticleId><ArticleId IdType="pubmed">7514955</ArticleId></ArticleIdList></Reference><Reference><Citation>Steck T., Westphal E., Wurfel W. Maternal immunization by husband’s leukocytes for repeated fetal death associated with mild pre-eclampsia—Case report with successful outcome. Arch. Gynecol. Obstet. 1992;252:103–107. doi: 10.1007/BF02389636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02389636</ArticleId><ArticleId IdType="pubmed">1471910</ArticleId></ArticleIdList></Reference><Reference><Citation>Rushmere N.K., Knowlden J.M., Gee J.M., Harper M.E., Robertson J.F., Morgan B.P., Nicholson R.I. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int. J. Cancer. 2004;108:930–936. doi: 10.1002/ijc.11606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.11606</ArticleId><ArticleId IdType="pubmed">14712499</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorter A., Blok V.T., Haasnoot W.H., Ensink N.G., Daha M.R., Fleuren G.J. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab. Investig. 1996;74:1039–1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">8667608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindranath N.M., Shuler C. Expression of complement restriction factors (CD46, CD55 &amp; CD59) in head and neck squamous cell carcinomas. J. Oral Pathol. Med. 2006;35:560–567. doi: 10.1111/j.1600-0714.2006.00466.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0714.2006.00466.x</ArticleId><ArticleId IdType="pubmed">16968237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesselring R., Thiel A., Pries R., Fichtner-Feigl S., Brunner S., Seidel P., Bruchhage K.L., Wollenberg B. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack. Eur. J. Cancer. 2014;50:2152–2161. doi: 10.1016/j.ejca.2014.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2014.05.005</ArticleId><ArticleId IdType="pubmed">24915776</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Yin R., Deng X., Shen H. Increased expression of CD55 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Clin. Investig. Med. 2012;35:E34–E39. doi: 10.25011/cim.v35i1.16104.</Citation><ArticleIdList><ArticleId IdType="doi">10.25011/cim.v35i1.16104</ArticleId><ArticleId IdType="pubmed">22309963</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Wang W., Xu L., Li L., Liu J., Feng M., Bu H. Immunohistochemical Expression and Prognostic Significance of CD97 and its Ligand DAF in Human Cervical Squamous Cell Carcinoma. Int. J. Gynecol. Pathol. 2015;34:473–479. doi: 10.1097/PGP.0000000000000200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PGP.0000000000000200</ArticleId><ArticleId IdType="pubmed">26107567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapka-Skrzypczak L., Wolinska E., Szparecki G., Wilczynski G.M., Czajka M., Skrzypczak M. CD55, CD59, factor H and factor H-like 1 gene expression analysis in tumors of the ovary and corpus uteri origin. Immunol. Lett. 2015;167:67–71. doi: 10.1016/j.imlet.2015.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2015.06.017</ArticleId><ArticleId IdType="pubmed">26261870</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowicki S., Nowicki B., Pham T., Hasan R., Nagamani M. Expression of decay accelerating factor in endometrial adenocarcinoma is inversely related to the stage of tumor. Am. J. Reprod. Immunol. 2001;46:144–148. doi: 10.1111/j.8755-8920.2001.460205.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.8755-8920.2001.460205.x</ArticleId><ArticleId IdType="pubmed">11506079</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray K.P., Mathure S., Kaul R., Khan S., Carson L.F., Twiggs L.B., Martens M.G., Kaul A. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol. Oncol. 2000;76:176–182. doi: 10.1006/gyno.1999.5614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/gyno.1999.5614</ArticleId><ArticleId IdType="pubmed">10637067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellone S., Roque D., Cocco E., Gasparrini S., Bortolomai I., Buza N., Abu-Khalaf M., Silasi D.A., Ratner E., Azodi M., et al. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: Implications for trastuzumab-based immunotherapy. Br. J. Cancer. 2012;106:1543–1550. doi: 10.1038/bjc.2012.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2012.132</ArticleId><ArticleId IdType="pmc">PMC3341945</ArticleId><ArticleId IdType="pubmed">22531721</ArticleId></ArticleIdList></Reference><Reference><Citation>Varsano S., Rashkovsky L., Shapiro H., Ophir D., Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin. Exp. Immunol. 1998;113:173–182. doi: 10.1046/j.1365-2249.1998.00581.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1998.00581.x</ArticleId><ArticleId IdType="pmc">PMC1905035</ArticleId><ArticleId IdType="pubmed">9717965</ArticleId></ArticleIdList></Reference><Reference><Citation>Durrant L.G., Chapman M.A., Buckley D.J., Spendlove I., Robins R.A., Armitage N.C. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 2003;52:638–642. doi: 10.1007/s00262-003-0402-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-003-0402-y</ArticleId><ArticleId IdType="pmc">PMC11034327</ArticleId><ArticleId IdType="pubmed">12811528</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimmino F., Avitabile M., Pezone L., Scalia G., Montanaro D., Andreozzi M., Terracciano L., Iolascon A., Capasso M. CD55 is a HIF-2alpha marker with anti-adhesive and pro-invading properties in neuroblastoma. Oncogenesis. 2016;5:e212. doi: 10.1038/oncsis.2016.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/oncsis.2016.20</ArticleId><ArticleId IdType="pmc">PMC4848835</ArticleId><ArticleId IdType="pubmed">27043658</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapka-Skrzypczak L., Wolinska E., Szparecki G., Czajka M., Skrzypczak M. The immunohistochemical analysis of membrane-bound CD55, CD59 and fluid-phase FH and FH-like complement inhibitors in cancers of ovary and corpus uteri origin. Cent. Eur. J. Immunol. 2015;40:349–353. doi: 10.5114/ceji.2015.54598.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ceji.2015.54598</ArticleId><ArticleId IdType="pmc">PMC4655386</ArticleId><ArticleId IdType="pubmed">26648780</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson K.L., Jones A., Norman S., Holmes C.H. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am. J. Pathol. 1997;151:1455–1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858073</ArticleId><ArticleId IdType="pubmed">9358772</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Chen H., Hu L., Xing Y., Sasaki T., Villosis M.F., Li J., Nishita M., Minami Y., Minoo P. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol. Biol. 2008;9:11. doi: 10.1186/1471-2199-9-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2199-9-11</ArticleId><ArticleId IdType="pmc">PMC2254434</ArticleId><ArticleId IdType="pubmed">18215320</ArticleId></ArticleIdList></Reference><Reference><Citation>Clines K.L., Clines G.A. DKK1 and Kremen Expression Predicts the Osteoblastic Response to Bone Metastasis. Transl. Oncol. 2018;11:873–882. doi: 10.1016/j.tranon.2018.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2018.04.013</ArticleId><ArticleId IdType="pmc">PMC6051964</ArticleId><ArticleId IdType="pubmed">29772510</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumia I., Pierani A., Causeret F. Kremen1-induced cell death is regulated by homo- and heterodimerization. Cell Death Discov. 2019;5:91. doi: 10.1038/s41420-019-0175-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-019-0175-5</ArticleId><ArticleId IdType="pmc">PMC6494814</ArticleId><ArticleId IdType="pubmed">31069116</ArticleId></ArticleIdList></Reference><Reference><Citation>Dun X., Jiang H., Zou J., Shi J., Zhou L., Zhu R., Hou J. Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma. Mol. Cancer. 2010;9:247. doi: 10.1186/1476-4598-9-247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-9-247</ArticleId><ArticleId IdType="pmc">PMC2949801</ArticleId><ArticleId IdType="pubmed">20846389</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen M.T., Mandrup O.N.A., Schelde K.K., Luo Y., Sorensen K.D., Dagnaes-Hansen F., Cameron J., Stougaard M., Steiniche T., Howard K.A. FcRn overexpression in human cancer drives albumin recycling and cell growth; a mechanistic basis for exploitation in targeted albumin-drug designs. J. Control Release. 2020;322:53–63. doi: 10.1016/j.jconrel.2020.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.03.004</ArticleId><ArticleId IdType="pubmed">32145268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M.H., Lee J.H., Lee J.S., Kim D.O.C., Yang J.W., An H.J., Na J.M., Shin M.C., Song D.H. Fc Receptor Expression as a Prognostic Factor in Patients with Non-small-cell Lung Cancer. Vivo. 2022;36:2708–2713. doi: 10.21873/invivo.13006.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/invivo.13006</ArticleId><ArticleId IdType="pmc">PMC9677804</ArticleId><ArticleId IdType="pubmed">36309388</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H., Hara A., Homma T., Yonekawa Y., Ohgaki H. Altered expression of immune defense genes in pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 2005;64:891–901. doi: 10.1097/01.jnen.0000183345.19447.8e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000183345.19447.8e</ArticleId><ArticleId IdType="pubmed">16215461</ArticleId></ArticleIdList></Reference><Reference><Citation>Cejas R.B., Ferguson D.O.C., Quinones-Lombrana A., Bard J.E., Blanco J.G. Contribution of DNA methylation to the expression of FCGRT in human liver and myocardium. Sci. Rep. 2019;9:8674. doi: 10.1038/s41598-019-45203-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-45203-1</ArticleId><ArticleId IdType="pmc">PMC6572836</ArticleId><ArticleId IdType="pubmed">31209240</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Meng G., Dickinson B.L., Li X., Mizoguchi E., Miao L., Wang Y., Robert C., Wu B., Smith P.D., et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J. Immunol. 2001;166:3266–3276. doi: 10.4049/jimmunol.166.5.3266.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.166.5.3266</ArticleId><ArticleId IdType="pmc">PMC2827247</ArticleId><ArticleId IdType="pubmed">11207281</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman N.M. Persistent Enterovirus Infection: Little Deletions, Long Infections. Vaccines. 2022;10:770. doi: 10.3390/vaccines10050770.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050770</ArticleId><ArticleId IdType="pmc">PMC9143164</ArticleId><ArticleId IdType="pubmed">35632526</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon E., Chen X., Mikaeloff F., Rodriguez J.E., Szekely L., Vinhas B.S., Krishnan S., Byrareddy S.N., Frisan T., Vegvari A., et al. Cell-type-resolved quantitative proteomics map of interferon response against SARS-CoV-2. iScience. 2021;24:102420. doi: 10.1016/j.isci.2021.102420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102420</ArticleId><ArticleId IdType="pmc">PMC8056843</ArticleId><ArticleId IdType="pubmed">33898942</ArticleId></ArticleIdList></Reference><Reference><Citation>Smirnova O.N.A., Ivanova O.N., Fedyakina I.T., Yusubalieva G.M., Baklaushev V.P., Yanvarev D.V., Kechko O.I., Mitkevich V.A., Vorobyev P.O., Fedorov V.S., et al. SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines. Cancers. 2023;15:632. doi: 10.3390/cancers15030632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15030632</ArticleId><ArticleId IdType="pmc">PMC9913867</ArticleId><ArticleId IdType="pubmed">36765590</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>